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ABSTRACT 
 
Full Name : Muhammad Monim-ul-Mehboob 
Thesis Title : Synthesis, characterization and anticancer activity of new gold (III) 
complexes with diamine and thione ligands  
Major Field : Chemistry 
Date of Degree : October 2013 
Since the hallmark discovery of anticancer properties of cisplatin, a large number of 
coordination compounds of platinum and other metals have been investigated for their 
anticancer potency. In recent years, gold complexes have demonstrated a great potential 
for the design and development of new anticancer agents. In view of this potential, we 
prepared several gold(III) complexes and evaluated their antitumor properties. 
In this dissertation, two novel series of gold(III) complexes are reported: the first consists 
of bis-diamines complexes while the second is mixed ligand series containing diamines 
and thiones. The first series of general formula, [Au(L)2]Cl3 [where L = 1,2-
diaminoethane (en), 1,3-diaminopropane (pn), N-alkyl substituted ethylenediamine (N-R-
en) and N,N´-diakyl substituted diamine] was synthesized by reacting auric acid 
trihydrate (HAuCl4·3H2O) with diamine ligands in 1:2 molar ratio. The second series of 
general formula, [(L´)2Au(L)]Cl3, where L = 1,2-diaminoethane (en), 1,3-
diaminopropane (pn), 1,4-diaminobutane (bn) and L´ = 1,3-imidazolidine-2-thione (Imt), 
1,3-Diazinane-2-thione(Diaz) and 1,3-Diazipine-2-thione (Diap)] was synthesized by 
reacting HAuCl4·3H2O with diamine and thione ligands in 1:1:2  molar ratio. 
These complexes of both series were subsequently characterized by elemental analysis, 
far-IR spectroscopy and solution as well as Solid state NMR measurements. The mid-IR 
and NMR data show the coordination of diamine ligands to Au(III) via N donor atoms. 
The crystal structure of one of the complexes was determined. The complex is dinuclear 
with two discrete [Au(pn)(Cl)]
+
 units bridged by two deprotonated pn ligands in a pseudo 
square planar coordination geometry at the Au(III) ion. The solid state IR as well as 
13
C 
xix 
 
and 
15
N NMR data for [(L´)2Au(L)]Cl3 complexes indicate that Au(III) centre is bonded 
via sulfur of thiocarbonyl S=C< site of the thiones and also chelated by the diamines. 
Spectroscopic data was essentially evaluated by comparing with calculated data from the 
built and optimized structure by GAUSSIAN 09 at the RB3LYP level with LanL2DZ 
bases set.  The computational study of [Au(en)2]Cl3 shows that the gold(III) adopts 
distorted square planar geometry. The structural features of [(L´)2Au(L)]Cl3 complexes 
based on thione and diamine mixed ligands are almost similar to [Au(en)2]Cl3 complex. 
The potential anticancer properties of gold(III) complexes were evaluated in vitro against 
prostate PC3, gastric SGC7901 and ovarian A2780/A2780 cis cancer cell lines. The third 
series, previously synthesized, with general formula, [Au(L)Cl2]Cl [where L 1,2-
diaminoethane (en), 1,3-diaminopropane (pn), 1,4-diaminobutane (bn)] was also used for 
comparison with [Au(L)2]Cl3.  Generally, [Au(diamine)2]
3+
 complexes demonstrate better 
anticancer properties in PC3 cells, whereas [Au(diamine)Cl2]
1+
 type displays better 
anticancer properties in SGC7901 and A2780/A2780 cis cells. The complex [Au(en)2]Cl3 
was recognized as most cytotoxic agent with activity as good as of clinically used drug 
cisplatin on prostate PC3 cancer cells. In this study, cytotoxicity data for second series of 
gold(III) complexes against C6 glioma cell lines are also reported, and the results indicate 
some complexes have cytotoxicity comparable to cisplatin. The in vitro cytotoxic study 
of Au(III)-thione complexes against C6 glioma cell line also leads to conclusion that the 
structural features e.g. ring size of thione ligand (Imt and Diaz) as well as Au(III) chelate 
ring size with diamine (en, pn and bn) may affect in vitro cytotoxicity of complex. The 
Imt containing Au(III) complexes are relatively better cytotoxic agents than those 
containing Diaz. Some of our complexes show in vitro cytotoxicity comparable to 
cisplatin. 
In order to investigate the mode of action of these compounds, experiments were 
performed on reactivity towards amino acids as potential binding partner in human body. 
The chemical and biological data presented in this dissertation provide the basis for not 
only understanding the existing status of gold-based anticancer drugs, but also a rationale 
for future drug design strategies.   
 xx
 
 ملخص الرسالة
 
 محمد  منعم المحبوب :املالاسم الك
 
و تقييم سميتها ضد مجموعة من الخلايا  III((سلسلة جديدة من معقدات الذهب  تصنييع و توصيف :عنوان الرسالة
 السرطانية
 
 الكيمياء :التخصص
 
 4116\11\6الموافق ل  1411 \11\ 26 :تاريخ الدرجة العلمية
 
فإنه قد تم البحث في عدد كبير من مركبات , مضادة للسرطان ال) nitalpsic(منذ إكتشاف السمة المميزة لخصائص 
خلال السنوات الحالية أظهرت . البلاتين التساهمية وغيره من المعادن لدراسة إمكانية إستخدامها كمضاد للسرطان
عدد هذه الامكانات قمنا بتحضير ل إدراكا. طوير عوامل مضادة للسرطانمعقدات الذهب إمكانات كبيرة في تصميم وت
 .وتقييم خصائصها المضادة للأورام) III(من معقدات الذهب 
 لك مختلط المتصلات من نوعذثنائي امينات و ك:  III((في هذه الاطروحة تم توثيق سلسلة جديدة من معقدات الذهب 
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السلسلة الثالثة للصيغة العامة والمحضرة . sic0872A/0872Aوالمبيض  1097CGSوالمعدة  3CPالبروستات 
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1 CHAPTER 1 
INTRODUCTION 
Platinum-based drugs such as cisplatin, carboplatin and oxaliplatin are among the most 
active anticancer agents and have been widely used in the treatment of a variety of 
cancers [1–15]. The structures of some platinum complexes effective as anticancer agents 
are shown in Figure 1.1. Cisplatin and carboplatin are known to be particularly effective 
against solid tumor types such as testicular, ovarian, head and neck cancers and, small-
cell lung cancer. Carboplatin has approximately the same spectrum of activity as cisplatin 
but reduced toxicity [12–14]. Oxaliplatin is particularly effective in the treatment of 
primary advanced colorectal cancer and cisplatin-resistant ovarian cancers [16–18]. 
 
 
Figure 1.1 Structures of some some anticancer platinum compounds 
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Although platinum-based drugs are widely used for the treatment of a variety of cancers 
[1–12] yet they are associated with severe side effects as well as acquired or intrinsic 
resistance [1]. These limitations encouraged scientists to investigate the complexes of 
other transition metals for example, palladium, ruthenium and gold. Among the non-
platinum transition metal complexes tested so far, gold complexes have demonstrated a 
great promise for the design and development of anticancer agents. 
Gold-based drugs, such as gold(I) thiomalate [myocrisin (Autm)n], gold(I) thioglucose 
[solganol (Autg)n] and auranofin [2,3,4,6-tetra-o-acetyl-1-thio--D-glucopyranosato-S) 
triethylphosphine gold(I)] have been successfully used over many years for the treatment 
of rheumatoid arthritis [19–22]. Besides curing arthritis, a large number of phosphine-
gold(I) complexes, especially, auranofin and [Au(dppe)2]Cl (dppe = 1,2-
bis(diphenylphosphino) ethane), are known to exhibit promising antitumor properties 
[23–27]. K[Au(CN)2] and gold(I) thiocyanate complexes have also been investigated as 
chemotherapeutic agents, including mainly the studies of antitumor and anti-HIV activity 
[28,29]. The structures of some important gold drugs with their trade names are shown in 
Figure 1.2. 
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Figure 1.2 Structures of some gold-based drugs 
In recent years, gold(III) complexes have become the focus of interest due to the reason 
that they are isoelectronic and generally isostructural to platinum(II) complexes such as 
cisplatin, the most widely used anticancer drug. It is, therefore, anticipated that they will 
have activity similar to that of platinum(II) antitumor drugs [30-34]. Cytotoxic activities 
of a number of gold(III) compounds have been evaluated. However, compared to gold(I) 
and platinum(II)-complexes, the gold(III) complexes have not been well explored 
chemically or electrochemically because they are highly reactive. Since gold(III) 
complexes have high redox potential and relatively poor stability, their use as anticancer 
drugs was questioned under physiological conditions [35].  
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Given that the mammalian environment is generally reducing, compounds of gold(III) 
were expected to be reduced in-vivo to gold(I) and metallic gold, which make them less 
effective as drugs. Recently, new gold(III) compounds with much higher stability have 
been synthesized using better ligands that usually have nitrogen atoms in the donor 
groups [36].  
Messori et al. described the in vitro activity of a series of gold(III) complexes, 
[Au(en)2]Cl3 (I), [Au(dien)Cl]Cl2 (II), [Au(cyclam)](ClO4)Cl2 (III), [Au(terpy)Cl]Cl2 
(IV), and [Au(phen)Cl2]Cl (V) as shown in Figure 1.3 against the A2780 ovarian cancer 
cell line and a cisplatin-resistant variant [33,37] The relative order of cytoxicity was 
Au(terpy) >> Au(phen) > Au(en), Au(dien) >> Au(cyclam). Interestingly the three most 
active compounds retained activity against the cisplatin-resistant cell line. All of these 
complexes showed significant cytotoxic effects against the A2780 human ovarian cancer 
cell line, comparable to or even greater than cisplatin, and they were able to overcome 
resistance to cisplatin to a large extent. 
A number of gold compounds have exhibited potent anticancer activity in in vitro assays 
against a number of human cancer cell lines [38–40]. Gold(III) complexes have been 
proved to be potent inhibitors of enzymes or proteins that are directly or indirectly 
involved in cancer growth and progression [41–43]. 
In the light of the above mentioned medicinal role of gold compounds, it is important to 
study the coordination chemistry of gold(III) from the point of view of designing new 
drugs as well as to understand the biochemical mechanism of action of the known 
anticancer complexes.  
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Figure 1.3 Structures of potential anticancer gold (III) poly-amine/imine complexes  
1.1 Current Status of the Problem  
1) Cisplatin has been used as an anticancer agent for the last few decades but found 
to be highly toxic.  
2) Carboplatin is a second-generation platinum drug against a limited number of 
cancers with relatively lower toxicity.  
3) Oxaliplatin was accepted for clinical use as recently as 2003 and used in 
combination with 5-fluorouracil against advanced metastatic colorectal cancers.  
4) Scientists are striving to develop new types of non-platinum drugs. The main aim 
is to design anticancer drugs with enhanced efficacy but low toxicity.  
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5)  Metal complexes offer an opportunity for the discovery of new antitumor drugs 
with truly new mechanisms of action by varying structural features in order to 
improve the physico-chemical and biological properties. 
6) Recent advances in this area demonstrated a great promise for the utilization of 
non-platinum complexes in cancer chemotherapy. 
7) Our interest in using gold for the development of anticancer agent arises from the 
fact that this metal has extensively been employed in medicinal inorganic 
chemistry during the last decades. 
8) Some gold(III) complexes, isoelectronic with antitumor platinum(II) complexes, 
have recently been evaluated in in vitro tests, showing significant cytotoxic 
effects.  
1.2 Aim of the Present Research 
1) The focus of the present study is to synthesize and characterize several new 
gold(III) complexes with a number of diamine ligands with the general formula, 
[Au(diamine)2]Cl3 as well as -mixed-ligands gold(III) complexes of diamines and 
thiones with the general formula, [(thione)2Au(diamine)]Cl3.  
2) The current work includes gold(III) complexes bidentate chelating ligands that is 
of  ethylenediamine (en) and propylenediamine (pn) type.  These en and pn are 
different sized ligands which will form chelate rings around Au(III) center. The 
thione ligands of different ring size i.e. Imidazolidine-2-thione (Imt),1,3-
Diazinane-2-thione (Diaz) and 1,3-Diazipane-2-thione (Diap) will also affect 
coordinating ability  towards Au(III) center. These different chelate size of 
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coordinated diamines and ring sizes of thiones are expected to demonstrate 
different reactivities and establish structure-activity relationships (SARs). 
3) Furthermore, we will also evaluate the newly synthesized complexes for their 
potential anticancer activity.   
The study is helped to lead us the discovery of new type of anticancer drugs.  If we are 
successful it will not only benefit the people who suffer from cancer in Kingdom of Saudi 
Arabia but also the cancer victims of the entire world. 
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2 CHAPTER 2 
LITERATURE REVIEW 
For half a century, the field of metal-based anticancer drugs has been dominated by the 
precious metal, platinum. The discovery of platinum’s anticancer properties was made 
unintentionally during an experiment in 1965 [44], conducted at Michigan State 
University by Barnett Rosenberg. He used a platinum electrode to apply an electric field 
to a colony of E. coli, which was observed to inhibit their growth [45]. A meticulous 
investigation into the cause of this effect concluded that the platinum electrode was 
breaking down to generate platinum-(II) species in situ, which was stopping the cells 
from multiplying. This observation led to the development of cis-
diamminedichloridoplatinum(II), commonly known as cisplatin, being approved by the 
American Food and Drugs Administration (FDA) for cancer therapy in December, 1978 
[46]. Since that it has become the most widely used anticancer drug, with an estimated 70 
% of patients receiving the compound as part of their treatment [47,48]. 
Cisplatin was heralded as a completely novel type of anticancer agent, and its discovery 
encouraged inorganic chemists to devise and test other precious metal-based therapies 
[49]. Metal compounds offer a huge unexplored chemical gap concerning modern drug 
design and development based on their different kinetics, geometries and reactivities 
compared to classical non-metal organic drugs.  
The fortuitous discovery of the anticancer properties of cisplatin, its platinum-(II) 
analogues and their wide clinical application in current cancer treatments promoted a 
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great deal of interest in the area of metal-based anticancer agents [50]. Cisplatin exhibits 
clinical activity against a wide range of different kinds of cancers. It remains one of the 
most significant anticancer agents in the clinical armamentarium [51]. However, it 
experiences both intrinsic and acquired resistance in cancer cell lines [52–55]. Cisplatin 
resistance is thought to occur primarily by cells resisting DNA platination leading to the 
exit at G2/M phase of cell cycle and inhibiting apoptosis. In addition, drug-efflux in 
resistant cell lines has been shown to be greater than the influx due to the up-regulation of 
multi drug resistance (MDR) genes and the production of antiporters such as glycoprotein 
[52]. 
Whilst the chemotherapeutic success of platinum is undeniable, it is by no means the 
perfect drug. It is not effective against many common types of cancer, drug resistance is 
common and it has a deplorable range of side effects, which can include nerve damage, 
hair loss and nausea. Disappointingly however, the countless clinical candidates in fifty 
years later, there have only been two more worldwide drug approvals for precious metal-
containing anticancer drugs: carboplatin and oxaliplatin, both of which are direct 
analogues of cisplatin, approved in 1993 and 2002 respectively. The mode of action of 
these platinum complexes is known: the chloride or dicarboxylate ligands are hydrolysed 
within the cell to generate a bis-aqua species, which binds irreversibly to DNA – usually 
to two adjacent guanine bases [56] and the cell, unable to replicate, defaults to apoptosis 
(controlled cell death) [49,57].  
Platinum-containing compounds such as cisplatin, carboplatin and oxaliplatin are widely 
used in the treatment of a variety of cancers. Newer, second generation platinum 
compounds like carboplatin and oxaliplatin were designed to improve efficacy 
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particularly against cell lines that demonstrate second pass cisplatin resistance [58]. 
Tolerance to cisplatin-induced DNA damage has been suggested as a fundamental 
mechanism of drug resistance [59]. 
In the early 1980s, the rapidly emergent interest as well as demand has enthused for the 
design of alternative platinum and non-platinum-based anticancer agents in cancer 
chemotherapy in order to overcome both intrinsic and acquired resistance in cancer cell 
lines. Consequently, in recent years the interest in non-platinum metal complexes for 
cancer chemotherapy has been rapidly growing. Such consideration has further been 
stimulated by the possibility of developing new agents with a different mode of action 
and clinical profile from the well-established platinum based metallodrugs [60]. 
To circumvent the problem of drug-resistance in cisplatin-resistant cells, gold(III)-based 
complexes have been designed as a potential alternative to cisplatin [61,62]. Gold(III) 
complexes exhibit iso-electronic and iso-structural features with platinum-(II) and have 
similar uptake and DNA interference activity [62]. In addition, the higher charge of 
gold(III) compared to platinum(II) is an added  advantage for binding with DNA [63]. 
Among the several classes of metal complexes that have been taken into consideration as 
potential anticancer agents starting from the 1980’s, only a few investigations have 
focused on d
8
 square planar gold(III) complexes in spite of their stringent similarity to 
platinum (II) complexes [64–68] 
In this context, a number of research reports are available in the literature on gold (I) 
drugs, but only a few reports appeared about the biological actions of gold(III) complexes 
[69,70]. However, owing to their relatively less solubility profile and being kinetically 
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more labile than the corresponding Pt(II) complexes, the gold(III) complexes were found 
to deviate from the platinum(II) compounds.  
During the 1990s, the gold(III) compounds  emerged as potential anticancer agents 
showing improved stability both in solid and solution phases, lower toxicity and 
favorable in-vitro pharmacological profiles. For example in 1996, Parish, Buckley, 
Elsome and co-workers reported a series of cytotoxic gold(III) compounds with tridentate 
damp ligands [damp = (dimethylamino)methyl]phenyl)] with encouraging results towards 
the anticancer activity (see Figure 2.1) [71–75]. Parish et al. also described [76] the 
chemical and biological studies of dichloroido-2-{(dimethylamino)methyl)phenyl}gold 
(III) complex. Abbate et al. [72] explained crystal structure and solution chemistry of the 
cytotoxic complex 1,2-dichloroido(o-phenanthroline)gold(III) chloride. 
N
Au
Cl
CH3
CH3
Cl  
Figure 2.1 Structure of [(Damp)AuCl2] 
We refer, in particular, to gold(III) porphyrinates (see Figure 2.2) [77], and to a variety of 
organogold(III) compounds [78]. Potent cytotoxic actions were investigated in vitro for 
most of the compounds. Some compounds are evidently shown the ability to overcome 
cisplatin resistance.  
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Figure 2.2 Representing structure of gold(III) porphyrin complexes 
Abbate et al. reported the crystal structure and solution chemistry of the cytotoxic 
complex 1,2-dichloro(o-phenanthroline)gold(III) chloride (see Figure 2.3) [72]. 
 
 
Figure 2.3 Structure of [{(Phen)AuCl2}Cl·H2O]2 
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In 2002, Marcon, Minghetti and Cinellu realized that some novel gold(III) complexes, 
bearing the bipyridyl  ligand (see Figure 2.4), might be favorably employed for anti-
proliferative effects on various  human cancer cell lines [35]. 
 
Figure 2.4 Schematic drawing of Au(III) bipyridine complexes 
S. Zhu et al. described the synthesis, structures, and electrochemistry of gold(III) 
ethylenediamine complexes and interactions with Guanosine 5'-Monophosphate [71]. 
Further, a number of other gold(III) complexes have been developed with anticancer 
activity. Gabbiani et al. elaborated a review on gold(III) compounds as anticancer drugs 
[31]. We refer, in particular, to gold(III) dithiocarbamates (see Figure 2.5) [79]. 
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Figure 2.5 Structures of gold(III) dithiocarbamate complexes [X=Cl or Br] 
In 2006, Casini et al. described a series of dinuclear gold(III) complexes with a “Au2O2” 
diamond core and with bypiridyl ligands  exhibiting interesting in vitro biological 
properties [80]. 
Several lines of evidence suggest that gold(III) compounds produce their antiproliferative 
effects through innovative and nonconventional modes of action. For instance, the 
hypothesis that their biological effects are mediated by an anti-mitochondrial mechanism 
rather than by direct DNA damage, as it is the case for cisplatin and its analogs, has 
gained much credit during the last few years. A. Bindoli et al. proposed thioredoxin 
reductase as a target for gold compounds acting as potential anticancer drugs [81]. Other 
targets were proposed in recent times such as the proteasome [82,83], histone 
deacetylases [84,85], a few kinases [86,87], transcription factors containing zinc finger 
motifs, etc.  
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Figure 2.6 Schematic drawings of dinuclear gold(III) oxo complexes. 
Figure 2.6 illustrates Auoxo type gold(III) complexes in which Auoxo3 is a ca. 1:1 
mixture of the cis and trans isomer while Auoxo4 and Auoxo5 are, as depicted, only 
trans isomers. 
It is now a quite accepted opinion that the remarkable cytotoxic effects documented for 
several gold compounds are mainly the consequence of metalation and inactivation of 
selected crucial proteins [88]. In contrast to the availability of such diverse anticancer 
agents as mentioned above, gastric and prostate cancer inhibiting gold(III) agents have 
rarely been explored. 
Maiore et al. recently evaluated gold(III) derivatives of 2-substituted pyridines for their 
biological and pharmacological behavior [88]. Palanichamy et al. identified four gold(III) 
compounds, [Au(Phen)Cl2]PF6, and its derivatives, exhibiting anticancer activity in both 
cisplatin sensitive and cisplatin resistant ovarian cancer cells [89].  Gabbiani et al. 
described remarkable anticancer properties in vitro for Au(III)bipy, Auoxo6 and Au2phen 
compounds [90]. Kouodom et al. suggested rational design of gold(III)-dithiocarbamato 
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peptidomimetics for the targeted anticancer chemotherapy [91].  Lessa et al. reported 
gold(I) and gold(III) complexes with glyoxaldehyde bis(thiosemicarbazones) as cytotoxic 
agents against human tumor cell lines and inhibition of thioredoxin reductase activity 
[92]. In this connection, an attractive strategy has astutely been designed to regulate the 
chemical and physical behavior of biologically pertinent tetra-coordinate gold(III) 
complexes. Such concept is executed by inclusion of appropriate bidentate ligands in the 
well-known gold(III) complexes having anticancer properties.  
Intrigued by these observations and motivated by our continued search to better 
understand the chemical and physical behavior of biologically relevant tetracoordinate 
gold(III) complexes, the compounds, [Au(en)2]Cl3 and [Au(N-pr-en)2]Cl3 have been 
prepared,  and subsequently characterized. Finally, their cytotoxicity has been tested in 
vitro in human gastric carcinoma SGC7901 cell line and prostate PC3 cancer cell lines. 
Other physicochemical studies like solution 
13
C as well as solid 
13
C,
 15
N NMR and DFT 
calculation studies were also performed.  
In this study, we tried to analyze the potential of [Au(en)2]Cl3  over its N-alkyl substituted 
analogue and to evaluate if it inhibits cancer cell proliferation or induction of slow 
growth of cancer cells. To the best of our knowledge, gold(III) diamine complexes and 
their derivatives have rarely been explored as anticancer agents against gastric, prostate 
and ovarian cancer cell lines. 
With such frame of mind, we have recently reported [Au(en)2]Cl3 (1) and [Au(N-pr-
en)2]Cl3 (4) complexes, demonstrating effective cytotoxicity against human gastric and 
prostate cancer cell lines [93–95]. [Au(Dach)2]Cl3 complexes have also been presented as 
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anticancer agents [96]. Such persuasive results triggered us to continue further studies on 
gold(III) complexes with various alkyldiamines ligands in order to investigate the effects 
of chelate ring size and basicity of amine-N of alkyldiamines ligands.  
Hence, new gold(III) diamine complexes have been prepared and characterized by 
various analytical  and spectroscopic techniques. Anticancer properties of a new series of 
Au(III) alkanediamine complexes, with general formulae of [LAuCl2]Cl and [Au(L)2]Cl3 
[where L = ethylenediamine (en), propylenediamine (pn), butylenediamine (bn) and N-
alkyl substituted ethylenediamine (N-R-en)], against a panel of cancer cell lines are 
reported here. The cytotoxic properties have been evaluated in vitro against human 
prostate PC3, gastric SGC7901 and ovarian A2780 / A2780 cis cancer cell lines. The 
effectiveness of these complexes (1-10) has been assessed in terms of IC50 on the 
SGC7901 and PC3 cancer lines, and compared to the commercially available cisplatin. 
The representative complexes (1) and (8) have also been studied as potential cytotoxic 
agents based on their IC50 data in the cisplatin-sensitive A2780 and cisplatin resistant 
A2780 cis ovarian cell lines.  
Metal complexes of heterocyclic thiones have found great interest in recent research due 
to their potential medicinal applications [97–102]. Considerable work has been carried 
out on thione complexes with gold(I) [103]. On the other hand, very little is known about 
gold(III) complexes with thiones. 
Heterocyclic thiones as ligands in metal complexes have attracted considerable attention 
because of their relevance to biological systems and the versatility in their coordination 
modes. These thiones are potentially ambidentate or multi-functional donors with either 
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the exocyclic S or heterocyclic N atoms available for coordination, thus yielding a variety 
of interesting complexes with geometries of variable nuclearity and great structural 
diversity [104]. 
Milavanovic et al. have evaluated in vitro the cytotoxic properties of [Au(en)Cl2]
+
 against 
chronic lymphocytic leukemia (CCL) cells and have shown comparable cytotoxicity 
profiles to cisplatin [105]. A. Casini et al. (2008)  have studied the anti cancer activities 
in a series of [Au(en)2]Cl3 type complexes. They reported that [Au(en)2]Cl3 showed 
similar activities compared to cisplatin [106].  
Our research group has recently reported that the [Au(en)Cl2]Cl complex causes minimal 
histological changes in kidney and liver of rats, reflecting its relative safety as compared 
to other clinically established anti-neoplastic drugs [95]. Likewise, we have reported 
[Au(en)2]Cl3 as a promising candidate as an anticancer agent [93]. For that reason, 
[Au(en)2]Cl3 might be a promising chemo-preventative and chemo-therapeutic agent 
against human gastric carcinogenesis.  
Such optimistic literature reports on Au(III) complexes prompted us to carry out the 
synthesis of a number of mixed-ligand complexes [Au(diamine)Cl2]
+
 with thiones such as 
Imt, Diaz and Diap. Accordingly, we have synthesized mixed ligand gold(III) complexes 
by using different diamines and thiones.  These complexes have been characterized by 
CHNS analysis, Solid state IR and solid as well as solution NMR spectroscopic methods.  
Finally, the prepared Au(III)-thione complexes have also been evaluated in vitro as 
cytotoxic agents against C6 glioma cancer cell line. 
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3 CHAPTER 3 
OBJECTIVES 
The aim of this research is to synthesize new gold(III) complexes as potential anticancer 
agents. The main goals of the research work are as follows: 
3.1 Synthesis of Gold(III) Complexes  
3.1.1 Synthesis of Gold(III) Complexes of Diamines  
The un-substituted and mono/dialkylsubstituted diamines as chelating bidentate ligands 
as shown in Figure 3.1 were used to synthesize the following gold(III) four coordinated 
complexes: 
i.  [Au(diamine)2]Cl3  
where diamine = 1,2-Diaminoethane(en) or 1,3-Diaminopropane(pn) 
ii.  [Au(N-alkyl-1,2-diaminoethane)2]Cl3  
where alkyl =Me, Et, n-Pr, iso-Pr  
iii. [Au(N,N´-dialkyl-1,2-diaminoethane)2]Cl3  
where alkyl =Me, Et, n-Pr, iso-Pr 
H2N
NH2
 
1,2-Diaminoethane(en) 
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H2N NH2  
1,3-Diaminopropane(pn) 
H2N
NH2
 
1,4-Diaminobutane(bn) 
H
N
H2N  
N-Methyl-1,2-diaminoethane (N-Me-en) 
H
N
H2N  
N-Ethyl-1,2-diaminoethane (N-Et-en) 
H
N
H2N  
N-n-Propyl-1,2-diaminoethane (N-n-Pr-en) 
H
N
H2N
 
N-iso-Propyl-1,2-diaminoethane (N-iso-Pr-en) 
H
N
N
H  
21 
 
N,N´-di-Methyl-1,2-diaminoethane (N,N´-di-Me-en) 
H
N
N
H  
N,N´-di-Ethyl-1,2-diaminoethane (N,N´-di-Et-en) 
H
N
N
H  
N,N´-di-n-Propyl-1,2-diaminoethane (N,N´-di-n-Pr-en) 
H
N
N
H
 
N,N´-di-iso-Propyl-1,2-diaminoethane (N,N´-di-iso-Pr-en) 
Figure 3.1 Structures of diamine ligands used in this study 
3.1.2 Synthesis of Gold(III) Complexes of Thione and Diamine Ligands  
The un-substitued diamine and thione ligands were used to synthesize the following 
gold(III) complexes: 
i.  [(thione)2Au(en)]Cl3  
ii. [(thione)2Au(pn)]Cl3  
iii. [(thione)2Au(bn)]Cl3 
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where en =1,2-diaminoethane (ethylenediamine), pn =1,3-diaminopropane 
(propylenediamine), bn= 1,4-diaminobutane (butylenediamine) and thione= 1,2-
imidazolidine-2-thione (Imt) or 1,3-Diazinane-2-thione (Diaz) or 1,4-Diazipane-2-thione 
(Diap) as shown in Figure 3.2 
 
Figure 3.2 Structures of thione ligands used in this study 
3.2 Characterization of Gold(III) Complexes   
The complexes 3.1.1 (i, ii and iii) and 3.1.2 (i, ii and iii) were characterized by melting 
point (MP) and elemental analysis (EA) techniques. 
N
H
H
N
S
Imidazolidine-2-thione
NH
NH
S
1,3-Diazinane-2-thione
NH
NH
S
1,3-Diazepane-2-thione
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3.3 Structural Analysis of Gold(III) Complexes  
The complexes were then structurally analyzed by Mid Infrared (MIR), Far Infrared 
(FIR) and Ultra-Violet (UV)/Visible (Vis) spectroscopic methods; 
1
H, 
13
C, 
15
N solution 
and 
13
C, 
15
N solid state Nuclear Magnetic Resonance (NMR) measurements. X-ray 
crystallography was employed for structure determination of crystalline complexes. 
3.4 Study of Anticancer Properties of Gold(III) Complexes  
The anticancer properties of gold complexes werer studied in-vitro against a panel of 
human cancer cell lines in order to evaluate their potential as possible anticancer agents. 
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4 CHAPTER 4 
EXPERIMENTAL 
4.1 Chemicals 
HAuCl4·3H2O was obtained from Strem Chemicals Co., while acetone, absolute ethanol, 
acetonitrile, D2O and CD3OD were obtained from Fluka Chemicals Co. 1,2-
Diaminoethane, 1,3-Diaminopropane, 1,4-Diaminobutane, N-ethyl-1,2-diaminoethane, 
N-propyl-1,2-diaminoethane and N-isopropyl-1,2-diaminoethane were purchased from 
Sigma Aldrich. N, N΄-dimethyl-1,2-diaminoethane, N, N΄-diethyl-1,2-diaminoethane, N, 
N΄-dipropyl-1,2-diaminoethane and N, N΄-diisopropyl-1,2-diaminoethane were obtained 
from Alfa Aesar. 
Imidazole, L-histidine and L-glycine were obtained from Sigma-Aldrich, L-
13
C3-
cysteine, L- methionine were obtained from Isotech, USA. Sodium tetrachloroaurate (III) 
dihydrate, Imidazolidine-2-thione (Imt), 1,3-Diazinane-2-thione (Diaz), 1,3-Diazipane-2-
thione (Diap), Imidazole, were purchased from Sigma-Aldrich. 
Potassium cyanide was purchased from Fisher Scientific Co. Potassium thiocynate was 
obtained from J. T. Baker Chemicals Co. The 
15
N label diamines ligands and 
15
N and 
13
C 
label potassium cyanide were obtained from Cambridge Isotope Labs, USA. All other 
reagents as well as solvents were obtained from Aldrich Chemical Co., and used as 
received.  
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4.2 Cell lines 
Human gastric SGC7901 and prostate PC3 cancer cell lines were provided by American 
Type Culture Collection (ATCC). Cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10 % Fetal Calf Serum (FCS), penicillin (100 kU 
L
-1
) and streptomycin (0.1 g L
-1
) at 37 ºC in a 5 % CO2 -95 % air atmosphere. MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) was 
purchased from Sigma Chemical Co, St.Louis, MO, USA. 
Human cisplatin sensitive A2780 and cisplatin resistant A2780 cis ovarian carcinoma cell 
lines were provided by the European Centre of Cell Culture (ECACC) Salisbury, UK. 
Cell culture reagents were purchased from Gibco-BRL, Basel, Switzerland. Glioma C6 
cancer cell line was obtained from ATCC, Georgetown University, Washington DC, 
USA. 
4.3 Synthesis of Gold(III) Complexes 
All reactions were generally carried out under an atmosphere of nitrogen using research 
grade chemicals and solvents. All complexes were subsequently characterized by melting 
point (MP) and elemental analysis (EA) techniques. Elemental analyses were performed 
on Perkin Elmer Series 11 (CHNS/O), Analyzer 2400. Melting points for complexes were 
carried out on BǕCHI 510 melting point apparatus.  
4.3.1 Synthesis of Gold(III) Diamine Complexes 
Gold complexes of ethylenediamine [Au(en)2]Cl3 and N-substituted ethylenediamine 
[Au(N-Pr-en)]Cl3 were prepared according to the reported procedures [71] and the purity 
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of these compounds was checked by elemental analysis. The procedure of synthesis is 
described here for [Au(pn)2]Cl3 complex. HAuCl4·3H2O (0.20 g, 0.50 mmol) was 
dissolved in 5 mL of deionized H2O. 1.0 mL of ca. 1.0 mmol aqueous solution of 1,3-
diaminopropane was added to this solution. An orange precipitate was formed after 
stirring for 3 hr. The precipitate was removed by filtration. The filtrate was kept in hood 
for crystallization after addition of 20 mL of ethanol. The very pale yellow precipitate, 
which formed immediately, was filtered off and air-dried [93–95]. Similar procedures 
were followed for the reported complexes (1-7) shown in Figure 4.1 as explained in 
Schemes I, II and III. Products were characterized by melting point (M.P.) and elemental 
analysis (EA) as given in Table 4.1. 
Using un-substituted diamines 
HAuCl4·3H2O + 2 en → [Au(en)2]Cl3 + HCl 
HAuCl4·3H2O + 2 pn → [Au(pn)2]Cl3 + HCl 
Scheme I 
Using substituted monoalkyl diamines 
HAuCl4·3H2O + 2 N-R-en → [.Au(N-R-en)2]Cl3 + HCl 
where R= Me, Et, nPr and iPr 
Scheme II 
Using substituted dialkyl diamines 
HAuCl4·3H2O + 2 N,N´-R2-en →[Au(N,N´-R2-en)2]Cl3 + HCl 
where R= Me, Et, nPr and iPr 
Scheme III 
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4.3.1.1 Preparation of [Au(pn)2]Cl3 complex  
HAuCl4·3H2O (0.20 g, 0.50 mmol) was dissolved in 5 mL of deionized H2O. 1.0 mL of a 
1.0 M aqueous solution of 1,3-diaminopropane (pn) was added to it. An orange 
precipitate formed, which was collected by filtration. 30 mL of ethanol was added to the 
filtrate. The very pale yellow precipitate was immediately formed. The precipitate was 
filtered off and air-dried [93–95].  
4.3.1.2 Synthesis of Crystalline Gold(III) Diamine Complex  
The suitable quality crystals for X-ray analysis were obtained by dissolving both 
HAuCl4·3H2O (0.21 g, 0.53 mmol) and pn (0.08 g, 1.08 mmol) in minimum volume of 
methanol. Both solutions were mixed and stirred for 2 hr. The yellow precipitate formed 
was separated by filtration. The filtrate was kept in the hood under the dark for the 
crystallization. After one week, light yellow crystals of [Au2(pn)2Cl2]Cl2·H2O complex 
were obtained. The crystalline product was characterized by melting point and elemental 
analysis (Table 4.1). 
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Table 4.1 Elemental analysis of Au(III) diamine complexes 
Complex 
M. P. Found (Calculated) % 
(ºC) %C %H %N 
[Au(en)2]Cl3 (1) 296 11.95(11.34) 4.14(3.81) 13.56(13.28) 
[Au(pn)2]Cl3 (2) 227-228 16.26(15.35) 4.94(4.72) 12.28(11.93) 
[Au2(pn)2Cl2]Cl2•H2O (2a) 235-237 10.37(10.29) 2.95(2.88) 7.89(8.00) 
[Au(N-Pr-en)2]Cl3 (4) 139-141 23.41(23.68) 6.20(5.48) 11.30(11.04) 
[Au(N-iPr-en)2]Cl3 (5) 107-109 24.54(23.66) 6.05(5.56) 11.38(11.04) 
[Au(N,N´-Et2-en)2] Cl3 (6) 210 28.68(26.90) 7.70(6.02) 11.43(10.46) 
[Au(N,N´-iPr2-en )2]Cl3 (7)  239 32.37(32.47) 7.66(6.81) 9.55(9.47) 
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Figure 4.1 Possible structures of gold(III) diamine complexes  
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4.3.2 Synthesis of Gold(III) Diamine and Thione Complexes 
Imidazolidine-2-thione (Imt), 1,3-Diazinane-2-thione (Diaz), 1,3-Diazipane-2-thione 
(Diap) were prepared according to the published procedure [98]. Firstly, 
[(diamine)AuCl2]Cl complexes were prepared according to the literature [94]. Later, 
[(diamine)Au(thione)2]Cl were synthesized as follows: 0.6 mmol of  [(diamine)AuCl2]Cl 
was dissolved in 20 mL distilled H2O (solution 1). 1.2 mmol of thione was dissolved in 
40 mL methanol (solution 2). Both solutions were mixed in a round bottom flask and 
refluxed at 60 
o
C for 2 hr. The resulting solution was filtered, concentrated and allowed 
to precipitate. The resulted precipitate was dried and the filtrate is kept in the refrigerator 
for crystallization. Products were characterized by melting point and elemental analysis 
(Table 4.2). Possible structures of gold(III) thione complexes are shown in Figure 4.2. 
Using Diamine and Imidazolidine-2-thione (Imt) 
HAuCl4·3H2O + diamine + 2 Imt → [(diamine)Au(Imt)2]Cl3 + HCl 
where diamine= en, pn and bn 
Scheme 1V 
Using Diamine and 1,3-Diazinane-2-thione (Diaz) 
HAuCl4·3H2O + diamine + 2 Diaz → [(diamine)Au(Diaz)2]Cl3 + HCl 
where diamine= en, pn and bn 
Scheme V 
Using Diamine and 1,4-Diazipine-2-thione (Diap) 
HAuCl4·3H2O + diamine + 2 Diap → [(diamine)Au(Diap)2]Cl3 + HCl 
where diamine= en, pn and bn 
Scheme VI 
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Table 4.2 Elemental analysis of Au(III) thione complexes  
Complex 
M.P. Found (Calculated) 
(
o
C) %C %H %N %S 
[(Imt)2Au(en)]Cl3 (11) 201 17.19(16.92) 3.73(3.55) 14.77(14.80) 11.19(11.30) 
[(Imt)2Au(pn)]Cl3 (12) 218 18.88(18.58) 4.05(3.81) 15.00(14.45) 11.04(11.02) 
[(Imt)2Au(bn)]Cl3(13) 172 20.30(20.16) 4.20(4.06) 14.19(14.11) 9.99(10.76) 
[(Diaz)2Au(en)]Cl3(14) 240 21.04(20.16) 4.28(4.06) 14.30(14.11) 9.91(10.76) 
[(Diaz)2Au(pn)]Cl3(15) 212 24.43(24.59) 5.06(5.31) 15.59(15.55) 10.00(9.38) 
[(Diaz)2Au(bn)]Cl3 (16) 269 23.18(23.31) 4.72(4.52) 13.50(13.47) 9.95(10.28) 
[(Diap)2Au(en)]Cl3(17) 203 24.49(24.59) 5.13(5.31) 15.41(15.55) 9.74(9.38) 
[(Diap)2Au(pn)]Cl3(18) 237 23.37(23.31) 4.67(4.52) 13.54(13.47) 10.01(10.28) 
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Figure 4.2 Possible structures of gold(III) thione complexes 
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4.3.3 Synthesis of Cyanido(diamine)Hg(II) complexes 
The mercury (II) complexes of diamines were prepared by mixing the solutions of 
selected diamine (3.5 mmol) and Hg(CN)2 (3.0 mmol) in methanol and refluxing  for 
about 4 hr as given in Schemes VII, VIII and IX. The res ulting colorless solution was 
filtered and kept in the refrigerator for crystallization. The products were obtained in 
good yields. They were characterized by melting point and elemental analysis (Table 
4.3). Possible structures of cyanido(diamine)Hg(II) complexes are shown in Figure 4.3. 
Using un-substituted diamines 
Hg(CN)2+ en → [(en) Hg(CN)2] 
Hg(CN)2+ pn → [(pn) Hg(CN)2] 
Scheme VII 
Using monoalkylsubstituted diamines 
Hg(CN)2+ N-Me-en → [(N-R-en) Hg(CN)2] 
Scheme VIII 
Using dialkylsubstituted diamines 
Hg(CN)2+ N-Nʹ-diR-en → [(N-Nʹ-diR-en) Hg(CN)2] 
where R=Me, Et, iPr 
Scheme IX 
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Table 4.3 Elemental analysis of Hg(II)(CN)2-diamine complexes  
Complex 
M.P. Found (Calculated) 
(ºC) %C %H %N 
[(en)Hg(CN)2] (19) 105 15.54(15.36) 2.78(2.58) 17.79(17.92) 
[(pn)Hg(CN)2] (20) 130 18.93(18.38) 3.23(3.08) 17.27(17.15) 
[(N-Me-en)Hg(CN)2] (21) 75-76 17.97(18.38) 3.38(3.08) 17.13(17.15) 
[(N, Nʹ-Me-en)Hg(CN)2] (22) 60-61 20.84(21.15) 3.33(3.55) 16.62(16.44) 
[(N, Nʹ-Et-en)Hg(CN)2] (23) 95-96 26.34(26.19) 3.44(3.85) 14.98(15.27) 
[(N, Nʹ-iPr-en)Hg(CN)2] (24) 50-52 29.99(30.42) 4.39(4.59) 14.29(14.19) 
 
 
 
Figure 4.3 Possible structures of Cyanido(diamine)Hg(II) complexes  
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4.3.4 Synthesis of Cadmium(II) and Mercury(II) Selenocyanate 
Complexes 
 
A solution of CdCl2 in 10.0 mL distilled water was mixed with equivalent stoichiometric 
amount of ligand (Histidine or Glycine) in 10.0 mL methanol-water mixture in 1:1 
volume ratio. The resulting solution stirred for 30 min, then two equivalents of KSeCN in 
water was added. The resulting mixture was refluxed with stirring under nitrogen gas for 
15 min then heated for ~ 1.5 hr at 70 
o
C. The product was filtered, washed and dried. A 
similar procedure was applied for mercury complexes using HgCl2 instead of CdCl2 as 
shown in Schemes X and XI. The products were characterized by melting point and 
elemental analysis (Table 4.4). Possible structures of Cadmium(II) and Mercury(II) 
selenocyanate complexes are shown in Figure 4.4. 
Using Glycine (Gly) and KSeCN as ligands 
MCl2 + Gly + 2 KSeCN→ [(Gly)M(SeCN)2] 
 
where M(II)=Cd(II) or Hg(II) 
 
Scheme X 
 
Using Histidine (His) and KSeCN as ligands 
 
MCl2 + His + 2 KSeCN→ [(His)M(SeCN)2] 
 
where M(II)=Cd(II) or Hg(II) 
 
Scheme XI 
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Table 4.4 Elemental analysis of Cd(II) and Hg(II) selenocyanate complexes  
Complex 
M. P. Found (Calculated) 
( C) %C %H %N 
[(Gly)Cd(SeCN)2] (25) D.P. at 184 1.32 (1.27) 12.15 (12.09) 10.78 (10.57) 
[(His)Cd(SeCN)2] (26) D.P. > 205 2.00 (1.90) 20.44 (20.12) 14.88 (14.67) 
[(Gly)Hg(SeCN)2] (27) >300 1.10 (1.04) 10.04 (9.89) 9.00 (8.65) 
[(His)Hg(SeCN)2] (28) D.P. >140 1.70 (1.60) 17.11 (16.99) 12.64 (12.38) 
 
 
 
 
 
Figure 4.4 Possible structures for M(II)) selencyante of Gly and His complexes 
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4.4 Spectroscopic Characterization 
4.4.1 Elemental Analysis 
Elemental analysis (EA) and melting points (M.P.) of gold(III) complexes were 
performed on Perkin Elmer Series 11 (CHNS/O), Analyzer 2400 and BǕCHI 510 
melting point apparatus respectively. The melting points and CHN/CHNS results of metal 
complexes are given in Tables 4.1, 4.2, 4.3 and 4.4.  
4.4.2 Mid-IR and Far-IR studies 
The solid state Mid-IR spectra of the ligands and their gold(III) complexes were 
performed on a Perkin–Elmer FTIR 180 spectrophotometer or NICOLET 6700 FTIR 
using KBr pellets over the range 4000–400 cm-1 and solid state Far-IR spectra were 
recorded for complexes at 4 cm
–1
 resolution at room temperature using CsCl disks on a 
Nicolet 6700 FT-IR with Far-IR beam splitter. 
4.4.3 UV-Vis Studies 
Lambda 200, Perkin-Elmer UV-Vis spectrometer was employed for recording and 
monitoring the electronic spectra. All electronic spectral data obtained for the gold (III) 
complexes were given in tabulated form.  
4.4.4 Solution state NMR measurements 
The solution 
1
H and 
13
C NMR experiments were performed on Jeol 500 MHz NMR 
Spectrometer at 297 K using ca. 0.10 M solution of the complexes in the deuterated 
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solvents (D2O, DMSO, CDCl3 and CD3OD. etc.). The 
1
H NMR spectra were obtained on 
a Jeol 500 MHz NMR spectrometer operating at a frequency of 500 MHz. 
13
C NMR 
spectra were obtained at 125.65 MHz with 
1
H broadband decoupling at 297K. The 
spectral conditions were: 32k data points, 0.967s acquisition time, 1.00 s pulse delay and 
45
o
 pulse angle. 
1
H and 
13C NMR Chemical shifts (δ) values were referenced to 
tetramethylsilane (TMS). 
15
N NMR spectra were obtained on Jeol 500 MHz Spectrometer operating at frequency 
50.55 MHz with 
1
H broadband decoupling at 297K. The spectral conditions were: 32k 
data points, 0.128 s acquisition time, 2.00 s pulse delay and 45
o
 pulse angle. 
15
N NMR 
chemical shifts (δ) values were referenced to -342.68 ppm of enriched 15NH4 NO3 in D2O 
solvent. 
4.4.5 Solid state NMR measurements 
Solid state NMR showed more sensitivity to coordination geometry rather than solution 
NMR, which is expected from the removal of the solvent effects, fluxional processes and 
other averaging processes that may be present in the solution state.  It has the added 
advantage that it provides the three principal components of the shielding tensor, rather 
than just the average value observed in solution spectra. These components can be 
calculated from the intensities of the spinning side bands in the Solid state spectra. Under 
the conditions of magic-angle spinning (MAS), the isotropic chemical shift I, given by 
Equation 1, is equivalent to the chemical shift observed in solution  
                             (Equation 1) 
39 
 
For a nonsymmetrical environment, with 11 < 22 <  33, the chemical shift anisotropy 
() is defined as 
                     (Equation 2) 
For a symmetric tensor, where 11 = 22 = ┴ , then 33 = // ; for 33 = 22 = ┴ , 
 then 11 = // . For these cases the shift anisotropy is defined as 
           (Equation 3) 
Unlike solution chemical shifts, solid state NMR results can be correlated directly with 
crystallographic structure determinations when available, and structural predictions can 
be made in the absence of crystallographic data.  
Solid state 
13
C NMR measurement  
The 
13
C{
1
H} solid state NMR spectra were obtained on a JEOL LAMBDA 500 
spectrometer operating at 125.65 MHz, corresponding to magnetic strength of 11.74 T. 
Samples were packed into 6 mm zirconium oxide rotors at ambient temperature of 278 K. 
Cross-polarization and high power decoupling were employed. Pulse delay of 7.0 s and a 
contact time of 5.0 ms were used in the CPMAS experiments. The magic angle spinning 
rates were from 2 kHz to 4 kHz. Carbon chemical shifts were referenced to TMS by 
setting the high frequency isotropic peak of solid adamantane to 38.56 ppm [107]. 
Solid state 
15
N NMR measurement  
Natural abundance 
15
N spectra were also recorded on a JEOL LAMBDA 500 
spectrometer, using a contact time of 5 ms and a pulse delay of 10 s. Samples were 
packed into 6 mm zirconium oxide rotors at ambient temperature of 278 K. Cross-
polarization and high power decoupling were employed. The magic angle spinning rates 
were between 2 kHz to 4 kHz. All 
15
N spectra were referenced to 
15
NH4NO3 peak (δiso) = 
40 
 
-358.63 ppm relative to CH3NO2, (δiso) = 0 ppm [108]. The 
15
N chemical shifts were 
referenced to an external enriched solid 
15
NH4Cl sample to 40.73 ppm [108] and 
converted to the standard CH3NO2 by a chemical shift of -380.0 ppm for NH3 [107]. The 
center peaks were differentiated from the spinning side-bands by recording the spectra at 
two different spinning speeds.  
Both the 
15
N spectra and 
13
C spectra, containing spinning side-band manifolds, were 
analyzed using a program HBA[109] based on Maricq and Waugh [110] which were 
developed at Dalhousie University, Canada, and University of Tübingen, Germany. 
Solid state 
199
Hg NMR measurement  
Solid state cross-polarization magic-angle spinning (CPMAS) 
199
Hg1H NMR spectra 
were obtained at ambient temperature of 298 K on the same spectrometer operating at a 
frequency of 89.30 MHz. Contact times of 20 ms were used with a proton pulse width of 
6 s, with a recycle delay of 10 s. Approximately 5000 FID (free induction decays) were 
collected and transformed with a line broadening of 100 Hz. Chemical shifts were 
referenced using an external sample of solid [Hg(DMSO)6](O3SCF3)2 with chemical shift 
Hg = -2313 ppm from Hg(CH3)2 [111]. 
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4.5 X-ray structure determination 
The crystal structure determination was carried out on Bruker Single Crystal X-ray 
Diffractometer. For crystalline gold(III) complexes, X-ray quality single crystals were 
mounted in a thin-walled glass capillary on a Bruker-Axs Smart Apex diffractometer 
equipped with graphite monochromatized Mo Kα radiation (λ = 0.71073 Å). The data 
were collected using SMART software [112]. The data integration was performed using 
SAINT [113]. An empirical absorption correction was carried out using SADABS [114]. 
The structure was solved with direct methods and refined by full matrix least square 
methods based on F
2
, using the structure determination package SHELXTL [115] based 
on SHELX 97 [116]. Graphics were generated using ORTEP-3 [117] and MERCURY 
[118]. For complex [Au2(pn)2Cl2]Cl2.H2O ], both of the hydrogen atoms of the disordered 
water molecule could not be placed reliably. All other H atoms were placed a calculated 
positions using a riding model. Crystallographic data, experimental and structure 
refinement details of complex (2a) are presented in Table 4.5.  
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Table 4.5 Crystallographic data and experimental details of crystal structure of (2a) 
Parameters Values 
Molecular formula C6H18Au2Cl2N4·2(Cl)·H2O 
Formula weight 699.99 
Crystal size/mm 0.40 × 0.33 × 0.27 
Wavelength/Å 0.71073 
Temperature/K 295 (2)  
Crystal symmetry Monoclinic 
Space group C2/c 
a/Å 28.864 (3)  
b/Å 8.4074 (7)  
c/Å 13.0740 (12)  
α/° 90 
β/° 91.377 (3)  
γ/° 90 
V/ Å
3
 3171.8 (5)  
Z 8 
Dc/Mg m
-3
 2.932 
μ(Mo-Kα)/mm-1 19.15 
F(000) 2544 
θ Limits/° 2.5–28.3 
Collected reflections 9266 
Unique reflections(Rint) 2266 
Observed reflections[Fo >2σ(Fo)] 2774 
Goodness of fit on F
2
 1.06 
R1(F), [I> 2σ (I)] 0.054 
wR2 (F
2), [I> 2σ(I)] 0.129 
Largest diff.peak, hole/e Å
-3
 2.86 
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4.6 Computational study 
The structures of some complexes were built and optimized using GAUSSIAN 09 
Revision A.1 program package [119] and GAUSSIAN 03, Revision B.04 program 
package [120] at DFT/B3LYP level with LANL2DZ (Los Alamos ECP plus double-zeta) 
basis set [121,122]. Geometry optimization for the built structures was also carried out 
using the same software program.  
4.7 Anticancer properties 
Human gastric cancer SGC7901 cells and prostate cancer cells PC3 were incubated. 
Trypan blue dye exclusion analysis and MTT assay were used to detect cell proliferation 
and assess the inhibitory effect of gold (III) complexes on the proliferation of SGC7901 
and PC3 cells.  In one culture plate, human gastric cancer SGC7901 and PC3 cells were 
treated with the gold(III) complex and the control (water) and in the second plate, only 
the [Au(en)2]Cl3 and SGC7901 cells were kept in these two sets for an entire day (24 h) 
and for 3 days (72 h). In other sets, compounds 1 and 4 with fixed concentration were 
employed to determine the growth inhibitory effect for both PC3 and SGC7901 cells. 
After being treated with compounds 1 and 4, cell viability was examined by MTT assay. 
4.7.1 Assessment of cell proliferation  
MTT assay was used to obtain the number of living cells in the sample. SGC7901 and 
PC3 cells were seeded on 96-well plates at a predetermined optimal cell density to ensure 
exponential growth in the duration of the assay. After 24 h pre-incubation, growth 
medium was replaced with experimental medium containing the appropriate drug or 
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control. Six duplicate wells were set up for each sample, and cells untreated with drug 
served as control. Treatment was conducted at 24 h and 72 h sequentially. After 
incubation, 10 μL MTT (6 g/L, Sigma) was added to each well and the incubation was 
continued for 4 h at 37 °C. After removal of the medium, MTT stabilization solution 
(dimethylsulfoxide: ethanol = 1:1) was added to each well, and shaken for 10 min until 
all crystals were dissolved. Then, optical density was detected in a micro plate reader at 
550 nm wavelength using an ELISA reader. Each assay was performed in triplicate. Cell 
number and viability were determined by trypan blue dye exclusion analysis. 
4.7.2  in vitro Cytotoxic assay for cisplatin sensitive prostate (PC3) and 
cisplatin resistance gastric (SGC7901) cells  
MTT assay was used to obtain the number of living cells in the sample. SGC7901 and 
PC3 cells were seeded on 96-well plates at a predetermined optimal cell density to ensure 
exponential growth in the duration of the assay. After 24 h pre incubation, growth 
medium was replaced with experimental medium containing the appropriate drug or 
control. Six duplicate wells were set up for each sample, and cells untreated with drug 
served as control. Treatment was conducted at 24, and 72 h respectively. After 
incubation, 10 μL MTT (6 g/L, Sigma) was added to each well and the incubation was 
continued for 4 h at 37 °C. After removal of the medium, MTT stabilization solution 
(dimethylsulfoxide: ethanol = 1:1) was added to each well, and shaken for 10 min until 
all crystals were dissolved. Then, optical density was detected in a micro plate reader at 
550 nm wavelength using an ELISA reader. Each assay was performed in triplicate. Cell 
number and viability were determined by trypan blue dye exclusion analysis. 
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Prostate PC3 and Human gastric SGC7901 cells were used in this study. Cells were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 % fetal 
calf serum (FCS), penicillin (100 kU L
-1
) and streptomycin (0.1 g L
-1
) at 37 ºC in a 5 % 
CO2 -95 % air atmosphere. Human gastric SGC7901 cells, prostate PC3 were incubated 
with these compounds at fixed concentrations or with water as control to assess the 
inhibitory effect on cell proliferation. The standard MTT assay has been used to assess 
inhibitory effect on cells growth. The cell survival versus drug concentration is plotted. 
Cytotoxicity was evaluated with reference to the IC50 value.  The half maximal inhibitory 
concentration (IC50) is a measure of the effectiveness of a compound in inhibiting 
biological or biochemical function. According to the FDA, IC50 represents the 
concentration of a drug or compound or complex that is required for 50 % inhibition in 
vitro. It is evaluated from the survival curves as the concentration needed for a 50 % 
reduction of survival. IC50 values are expressed in M [123]. IC50 values were calculated 
from dose-response curves obtained in replicate experiments.   
4.7.3 in vitro Cytotoxic assay for cisplatin sensitive (A2780) and 
cisplatin resistance (A2780 cis) ovarian cancer cell line  
Adrent human ovarian adenocarcinoma (A2780) cells  and cisplatin-resistant ovarian 
(A2780 cis) cells were cultured in complete RPMI 1640 medium containing 100 
units/mL penicillin, 100 g/mL streptomycin and 10 % fetal bovine serum (FBS). The 
cisplatin-resistant cell line A2780 cis is developed by chronic exposure of the parent 
cisplatin-sensitive A2780 cell line. In order to retain resistance, 1 µM cisplatin needed to 
add to the media for A2780 cis every 2-3 passages. The two cell lines were grown at 37 
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o
C in a humidified atmosphere of 95 % air and 5 % CO2.  Experiments were performed 
on cells within 10 passages. Viable cells were counted using the trypan blue exclusion 
method. 
Drug effects on exponentially growing cancer cells were determined using MTT assay. 
A2780 and A2780 cis cells were seeded at a density of 6,000 cells/100 µL per well in 96-
well plates and allowed to attach for 24 hr at 37 °C under 5 % CO2. After the attachment 
period, cancer cells were exposed to drugs at different concentrations in RPMI 1640 
medium without FBS and antibiotics. Sample solutions were prepared by dissolving in 
water and diluted with water to a series of different concentrations. The final 
concentration of water in medium was 1 % v/v. After 6 hr drug exposure, the medium 
with sample solutions at different concentrations was removed by aspiration and fresh 
drug-free complete medium with FBS and antibiotics were added and the cells were 
incubated for additional 66 h. At 72 h after drug addition, 100 µL MTT reagents (0.5 
mg/mL in PBS) were added to each well after removal of medium, and cells were 
incubated for a further 4 h at 37 °C. Later, the MTT reagent was discarded, and the purple 
precipitate was dissolved in 100 µL DMSO. The absorbance of formazan, a metabolite of 
MTT, in the resulting solution was photometrically measured at a wavelength of 595 nm 
using a microplate reader (Tecan Instruments Inc., Research Triangle Park, NC, USA). 
Experiments were performed in three replicate wells for each drug concentration and 
carried out independently at least three times.  
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4.7.4 Assay for inhibitory effect of [(diamine)AuCl2]
1+ 
complexes (8-10) 
on prostate (PC3) and gastric (SCG7901) cancer cells 
MTT assay was used to obtain the number of living cells in the sample. Human gastric 
cancer SGC7901 and prostate cancer PC3 cells were seeded on 96-well plates at a 
predetermined optimal cell density i.e.ca 6,000 cells/100 µL per well in 96-well plates to 
ensure exponential growth in the duration of the assay. After 24 h pre incubation, growth 
medium was replaced with experimental medium containing the appropriate drug using 
Au (III) diamine complex or control using water. Six duplicate wells were set up for each 
sample, and cells untreated with drug served as control. In one sets of culture plate, 
human gastric cancer SGC7901 and human prostate PC3 cells were treated with the 
complexes (1), (4) and (8-10) as drug and the control (water) for 24, 48 and 72 h. In other 
sets, complexes (1), (4), and (8-10) with fixed concentration i.e. 10 µM were employed to 
determine the growth inhibitory effect for both PC3 and SGC7901 cells separately.  After 
incubation, 10 μL MTT (6 g/L, Sigma) was added to each well and the incubation was 
continued for 4 h at 37 °C. After removal of the medium, MTT stabilization solution 
[Dimethylsulfoxide (DMSO): Ethanol = 1:1] was added to each well, and shaken for 10 
min until all crystals were dissolved. Then, optical density was detected in a micro plate 
reader at 550 nm wavelength using an Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
reader. After being treated with Au(III) diamine complexes, cell viability was examined 
by MTT assay. Each assay was performed in triplicate. MTT assay for inhibitory effect 
has been used for complexes (8-10) against PC3 and SGC7901 cells. These cells were 
treated with various concentrations of complexes (8-10) for 24-72 h. The results are 
shown in Figures 2-7. 
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4.7.5 in vitro Cytotoxicity of Au(III)thione complexes on C6 glioma cells 
C6 glioma cells were seeded at 2 x 10
4
 cells/well in 100μL DMEM,  containing 10 % 
FBS in 96-well tissue culture plate, and incubated for 72 h at 37 
o
C, 5 % CO2 in air and 
90 % relative humidity in CO2 incubator in order to evaluate the in vitro cytotoxicity of 
[(thione)2Au(diamine)]Cl3 complexes (11-16). 
160, 80, 40, 20, 10 and 5 μg/mL sample solutions were prepared in DMEM. 100 μL of 
each sample solution were added to the incubated C6 glioma cells and further incubated 
for 20 hours.  The medium was discarded and 100 μL DMEM containing MTT (5 
mg/mL) was added to the same cells and again incubated in CO2 incubator at 37 
o
C in 
dark for 4 h. The dark purple crystals of formazan were produced in the cells at the 
bottom of the wells.  
The medium of culture from each well was aspirated cautiously to prevent disruption of 
the cell monolayer. 100 μL of DMSO was added in each well and mixed thoroughly to 
dissolve the formazan crystals, producing a purple solution. The absorbance of the 96 
well plates was taken at 570 nm with Labsystems Multiskan EX-ELISA (Enzyme-linked 
immune-sorbent assay) reader against a reagent blank. 
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4.8 Biological activity 
The biological activity of cyanido(diamine)Hg(II) and M(II)selenocyanate complexes 
[M(II)=Cd(II) or Hg(II)] are evaluated by antimicrobial assay and test for bacterial strain 
(antibacterial assay) respectively. 
4.8.1 Antimicrobial assay 
Antimicrobial activity was measured as described in the literature [124,125]. It was 
evaluated by the minimum inhibitory concentration (MIC) on four microorganisms, 
namely Escherichia coli (E.Coli), Heterotrotropic Plate Counts (HPC), Pseudomonas 
aeruginosa (P. aeruginosa) and Fecal Streptococcus (FS).  Each analysis was carried out 
in duplicate to maintain the maximum accuracy. Dosage of each chemical started from 10 
g/ml and continued until MIC was reached. A maximum dose of 1000 g/ml was used 
as a stopping criterion. The complex (19) and its derivatives (21-24) are relatively 
insoluble in water however; the bioactivities are carried out in water. As tested complexes 
are more soluble in DMSO, analysis is repeated for all the compounds in duplicate. 
Complexes were dissolved in water and in DMSO separately to note any effect of 
solubility. Some of the results show slight improvement in DMSO as compared to water.  
However, it should be noted that solutions prepared in water was kept in shaker prior to 
analysis at least for 24 hr and a homogenous sample was used for analysis. 
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4.8.2 Antibacterial assay  
Standard type culture of Escherichia coli (MTCC 443), Klebsiella pneumoniae (MTCC 
109), Pseudomonas aeruginosa (MTCC 1688), Salmonella typhi (MTCC 733) and 
Staphylococcus aureus (MTCC 737) were obtained from Microbial Type Culture 
Collection (MTCC) Chandigrah India. The agar well diffusion technique [126] was used 
to screen the antibacterial activity. Antibacterial activities were screened in vitro by using 
nutrient agar plates obtained from Himedia (Mumbai). The plates were prepared by 
pouring 20 ml of molten media into a sterile Petri dish and allowed to solidify for 5 
minutes.  A sterile cork borer of diameter 6.0 mm was used to make wells in the agar 
plates. Inoculums were swabbed uniformly on the surface of agar plates. 0.1 mg/well 
were loaded on 6.00 mm diameter well. The plates were allowed to stand for 1 h for 
diffusion then incubated at 37 ° C for 24 h. At the end of incubation, inhibition zones 
were measured. 
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4.9 Interaction studies of Gold(III) complexes using NMR 
spectroscopy 
Interaction of the gold(III) complexes with some biologically important ligands has been 
studied using 
1
H and 
13
C NMR measurements.  
4.9.1 NMR measurements  
All NMR measurement were carried out on a JEOL LAMBDA 500 MHz NMR 
spectrophotometer at 298 K using 0.05 M solution of [Au(pn)2]Cl3 complex (Figure 4.5) 
in D2O. 
13
C NMR spectra were obtained at 125.65 MHz with 
1
H broadband decoupling. 
The spectral conditions were: 32 k data points, 0.967 s acquisition time, 1.00 s pulse 
delay and 45˚ pulse angle. 
NMR samples were prepared by mixing [Au(pn)2]Cl3 complex in D2O with 
Imidazolidine-2-thione, Thiourea,  Glycine, Methionine, Histidine and Imidazole ligands 
abbreviated as Imt, Tu, Gly, Met, His and Im as shown in Figure 4.6 respectively in 1:1 
molar ratio in order to study the interaction between them. 
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Figure 4.5 Structures of pn and [Au(pn)2]Cl3 complex 
 
Figure 4.6 Structures of ligands used in the NMR studies of interactions 
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5 CHAPTER 5 
RESULTS AND CONCLUSION 
5.1 Gold(III) Diamine Complexes  
This work reports the synthesis of some [Au(diamine) 2]Cl3 complexes where diamine = 
1,2-diaminoethane (en), 1,3-diaminopropane (pn), alkyl-substituted 1,2-diaminoethane 
(N-R-en) and diakyl-substituted 1,2-diaminoethane (N,Nʹ-R2-en). 
5.1.1 Mid-IR Studies  
The characteristic mid-IR vibration bands for the free ligands and their corresponding 
gold(III) complexes are shown in Table 5.1. Solid state IR spectrum of complex (1) 
shows clear signals for the presence of N-H frequency at 3396 cm
-1
, while in case of 
complex (4), the N-H frequency appears at 3538 cm
-1
 indicating the strong coordination 
of ligand with the metal center. The C–N stretching bands showed a slight shift to higher 
frequency in the complex. It indicates a shorter C–N bond in the complex as compared to 
the free ligand. 
Solid state IR spectra of complexes (2) and (2a) showed signals for the presence of N-H 
vibration at 3413 and 3442 cm
-1
 respectively. The C–N stretching bands in the complexes 
(2) and (2a) showed a large shift to higher wave numbers 1203 and 1198 cm
-1 
respectively, indicating that the C–N bond in the complex is relatively stronger than that 
in the free pn ligand. The N-H band appears at much higher frequency in N-alkyl-
54 
 
substituted diamine complexes than that in the unsubstituted diamines complexes [93]. 
For example, the N-H frequency shift is about 150 and 180 cm
-1  
in complexes (3) and (4) 
respectively, while this shift is about 56 cm
-1 
in complex (2). The larger N-H wave 
number shifts designate the strong coordination of ligands in complexes (3) and (4) with 
the gold(III) centre.  This may be due to lone pair donation to the gold(III) center, which 
is facilitated by the alkyl group bound directly to the nitrogen donor atom as substituent. 
Table 5.1 Mid-IR frequencies, ν(cm-1) for Au(III) diamine complexes 
Compound ν(N-H) ν(C-N) 
en
b
 3393 1093 
(1) 3396 1043 
pn 3357 m, 3282 m 1093 w 
(2) 3413 1203 
(2a) 3442 1198 
N-Et-en 3276 br 1130 m 
(3) 3426 1042 
N-pr-en
a
 3358 m 1127 
(4) 3538 1163 
N-ipr-en 3300 m, 3289 m 1174 m 
(5) 3476 1124 
a 
Published work [93]
 
and 
 b 
Published work [94] 
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5.1.2 Far-IR studies  
The characteristic Far-IR vibration bands for the free ligands and their corresponding 
gold(III) complexes are shown in Table 5.2. There is a characteristic stretching frequency 
at 367 cm
-1
 for Au-Cl bond in trihydrate auric acid (HAuCl4·3H2O). The absence of such 
stretching band in bis(diamine) gold(III) indicating the replacement of two monodentate 
chloride by bidentate diamine ligands. That is also confirmed by the presence of 
stretching frequencies of Au-N bond indicating coordination of diamine via N-donor 
atoms to gold(III) center. Far-IR data showed signals at 378 and 476 cm
-1
 & 375 and 415 
cm
-1
 that could be assigned for the stretching frequencies of the Au–N bond of complexes 
[Au(en)2]Cl3(1) and  [Au(N-Pr-en)2]Cl3  (4) respectively [94,127]. 
Table 5.2 Far-IR frequencies, ν(cm-1) for Au(III) diamine complexes 
Compound ν(Au-Cl) ν(Au-N) 
HAuCl4·3H2O  367 -- 
[Au(en)2]Cl3 (1) -- 378, 476 
[Au(N-Pr-en)2]Cl3 (4) -- 375, 415 
a
 Published work [94] 
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5.1.3 UV-Vis studies  
UV-Vis data showed absorption in the region of 250–350 nm (40000–28570 cm-1) which 
correspond to LMCT (Ligand to metal charge transfer) transitions. The absorption 
spectrum of trihydrate auric acid HAuCl4·3H2O gives a characteristic absorption band at 
320 nm [128]. Therefore, a signal at 300 nm with high extinction coefficient (Ɛ) could be 
assigned to Cl→Au charge transfer. Such a transition of high extinction coefficient 
cannot be assigned to the symmetry forbidden d–d transition. According to crystal field 
theory, the LUMO orbital is dx2-y2 for d
8
 complexes, so LMCT (ligand to metal charge 
transfer) could be due to pσ→dx2-y2 transition. It is also evident that the electronic spectra 
of these compounds are stable and consistent which means that the gold center remains in 
+3 oxidation state. 
5.1.4 Solution state NMR studies 
Table 5.3 shows the 
13
C NMR chemical shifts of diamine ligands and their corresponding 
gold(III) complexes in solution. Downfield shifts were observed for 
13
C resonances in the 
gold(III) complexes relative to the free diamine ligands. There is third non-equivalent 
carbon directly bonded to NH due to deprotonation of NH2 in coordinated pn: 
NHCH2CH2CH2NH2 of complex (2a). These downfield shifts may be due to the σ-
donation of nitrogen lone pair to the metal center that causes the deshielding of the 
carbons adjacent to the coordinating-NH groups. The downfield shift is greater for the 
substituted diamine ligand than that for the unsubstituted diamine ligand. For example, in 
case of complex (2), the change in chemical shift of C1 signal is observed as 3.37 ppm, 
while in case of complexes (3) and (4), the change in chemical shift of C-1 signal 
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observed is 13.64 and 7.78 ppm respectively. Similar trend of change in chemical shift 
has been observed in complex (5). 
A significant downfield shift was observed at 50.69 ppm for complex (1) with respect to 
the free ethylenediamine (en) ligand at 37.32 ppm (Table 5.3). This can be attributed to 
the donation of nitrogen lone pair to the gold that causes deshielding of the carbon(s) next 
to the bonding nitrogen. But the upfield shift of compound [Au(en)2]Cl3 (1) as compared 
to [(en)AuCl2]Cl (8) may be due to the lone pair donation of nitrogen is slightly less 
effective as compared to that of the compound (8) which is having two Cl
-
 atom directly 
bonded to gold. It is also worth-mentioning that the only one signal at 50.69 ppm for 
[Au(en)2]Cl3 (1) indicates that the tetra-coordinate gold(III) complex is adopting the 
regular square planar geometry thereby causing two carbons in similar environment. But 
the shifts vary significantly from one ligand to the other, suggesting different degrees of 
σ-donation from the ligand to the metal (Table 5.3). For instance, complexes 
[Au(en)2]Cl3 (1) and [Au(N-Pr-en)2]Cl3 (4) even though they have the same basic 
skeleton of ethylenediamine (en), the chemical shifts of the C-1 and C-2 carbons of 
[Au(N-Pr-en)2]Cl3 (4) appear at 48.61 and 57.52 ppm respectively. The chemical shifts of 
C-2 and C-3 of the ligand in complexes (1, 4 and 6) demonstrate that they are in similar 
environment even after complexation with the metal center. It is may be due to cyclic 
bond strain for the endo-cyclic carbon atom of metal chelate. Such a higher shift is may 
be as a result of inductively withdrawing effect of the nitrogen atom which is coordinated 
to the gold(III). 
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Table 5.3 Solution state13C NMR chemical shifts of Au(III) diamine complexes 
Compound 
13C (δ in ppm) 
C-1 C-2 C-3 C-4 
en
a
 37.32     
 
(1) 50.69       
pn 37.61 25.79   
 
(2) 40.98 27.94   
 
(2a) 40.66 26.31 38.06*   
N-Et-en 36.41 44.4 44.37 11.42 
(3) 50.05 57.38 49.1 10.59 
N-pr-en
a
 40.83 51.41 51.63 22.8 
(4) 48.61 57.52 58.03 36.39 
N-ipr-en 36.58 42.27 52.58 19.07 
(5) 37.95 52.29 57.52 21.26 
a
Published work [93] 
* 
Third non-equivalent carbon directly bonded to NH due to deprotonation  in 
coordinated pn NHCH2CH2CH2NH2 ligand of complex (2a) 
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5.1.5 Solid state NMR 
The 
13
C and 
15
N CPMAS NMR spectral data for complexes (1) and (2) are shown in 
Table 5.4. It is observed that 
13
C isotropic chemical shift of diamines moves towards 
downfield region upon coordination as compared with the free ligands. A similar trend 
has been observed in 
13
C solution state NMR. 
In the case of solid state NMR spectroscopy, we observe only the isotropic signals due to 
the carbon and nitrogen indicating small anisotropies due to the sp
3
 hybridizations of 
these atoms. The chemical shift of 51.82 ppm
 
in Solid state 
13
C NMR, for complex (1) is 
slightly higher than that of the solution NMR chemical shift 50.69 ppm (Table 5.4) which 
is a clear indication of the stability of the prepared complex as well as the conservation of 
the bond topology in solution as in the solid form. The 
15
N NMR chemical shift for 
[Au(en)2]Cl3 is -317.36 while for 1,2-ethylenediamine dihydrochloride (en·2HCl), it 
appeared at -342.68 ppm. This deshielding can be attributed to the lone pair electron 
donation of the nitrogen atom of ethylenediamine (en) ligand to gold(III). 
Recently, Mironov and Afanas'eva published data on complex (2) [129]. These authors 
reported that a ring-open form of complex (2) is possible.  However, our solution and 
solid 
13
C NMR data indicate only two resonances as given in Table 5.3 and Table 5.4 
respectively. This clearly shows that complex (2) is a bis-chelated of gold(III). The open 
chain complex should give more than two resonances in 
13
C NMR. This is also 
corroborated by solid state 
15
N NMR data in which only one 
15
N signal is observed. 
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Table 5.4 Solid state 13C and 15N NMR data of Au(III) diamine complexes 
Compound 
15
N 
13
C 
15
NH2 C-1 C-2 
en•HCla -342.68 37.79 
 
[Au(en)Cl2]Cl
a
 (6) -342.09 53.76 
 
[Au(en)2]Cl3
b
 (1) -317.36 51.82   
pn•HCl -343.12 37.81 26.17  
[Au(pn)2]Cl3 (2) -365.28 41.34 30.95 
a
Published work [94] and 
b
Published work [93] 
5.1.6 Crystal structure of complex (2a) 
The crystal structure of complex (2a) is shown in Figure 5.1. Selected bond lengths and 
bond angles are given in Table 5.5 and Table 5.6. It is a dinuclear ionic complex with two 
[Au(pn)(Cl)]
+ 
units bridged by two deprotonated  molecules of 1,3-propylenediamine 
ligand. There are two chloride ions and one water molecule in the outer sphere of the 
complex. The coordination geometry around the Au(III) ions is pseudo-square planar and 
each metal atom is coordinated by two NH and one NH2 donor groups of the two 
deprotonated 1,3-propylenediamine bridging ligand molecules, and one chloride anion. 
The dinuclear cations contain two six-member chelate cycles AuN2C3 and the four-
member cycle Au2N2. 
In the central Au2N2 four-member ring of the dimer complex Au2–N1 & Au2–N3 bond 
distances 2.039 (1) & 2.019 (1) Å are shorter than Au1–N1 & Au1–N3 bond distances 
2.048 (1) & 2.052 (1) Å. The Au-N bond distances vary from 2.019 (1)–2.052 (1) Å and 
correspond to those found in the amine Au (III) complex [130] Au1–Cl1 and Au2–Cl2 
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bond lengths are 2.298 (4) and 2.288 (4) Å respectively as given in Table 5.12. The N–
Au1–N and N–Au2–N bond angles vary in the ranges 79.0 (4)–174.9 (4) ° and 80.0 (4)–
173.6 (5) ° respectively. The bond angles around both gold(III) ions in binuclear complex 
are different from each other. These observations provide an additional evidence for the 
presence of slightly different geometry around both gold(III) ions in this binuclear 
complex. 
In this binuclear complex the Au
…
Au distance [3.0549 (8) Å] is longer than the one 
reported [3.004 (2) Å] for Au(III) complexes with primary amine ligands [130–132]. This 
metal
…
metal distance is also longer than the one in metallic gold [2.884 Å]. However, it 
is short enough to illustrate aurophilic (Au
…
Au) interaction in complex (2a). The 
presence of Cl
–
 counter ions, lattice water molecule and –NH, –NH2 groups of the 1,3-
propylenediamine ligand result in hydrogen bond formation in the solid state structure of 
compound (2a), which leads to the formation of a three-dimensional hydrogen bonded 
network as shown in Figure  5.2 and Figure  5.3. 
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Table 5.5 Selected bond lengths (Å) for the crystal structure of complex (2a) 
Bond  Length (Å) 
Au1—Cl1 2.298 (4) 
Au2—Cl2 2.288 (4) 
Au1—N2 2.041 (12) 
Au1—N3 2.039 (12) 
Au1—N1 2.019 (11) 
Au1—Au2 3.0549 (8) 
Au2—N4 2.042 (12) 
Au2—N3 2.048 (11) 
Au2—N1 2.052 (11) 
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Table 5.6 Selected bond angles (º) for the crystal structure of complex (2a) 
Bonds   Angle (°) 
N1—Au1—N2 94.5 (5) 
N1—Au1—N3 80 (4) 
N2—Au1—N3 173.6 (5) 
N1—Au1—Cl1 176.3 (3) 
N2—Au1—Cl1 89.1 (4) 
N3—Au1—Cl1 96.4 (3) 
N1—Au1—Au2 41.8 (3) 
N2—Au1—Au2 133.9 (3) 
N3—Au1—Au2 41.7 (3) 
Cl1—Au1—Au2 134.99 (11) 
N4—Au2—N3 95.9 (5) 
N4—Au2—N1 174.9 (4) 
N3—Au2—N1 79 (4) 
N4—Au2—Cl2 89.2 (3) 
N3—Au2—Cl2 174.4 (3) 
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Figure 5.1 A view of the molecular structure of the dimeric complex (2a) 
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Figure  5.2  View of the hydrogen bonded network of complex (2a) in the unit cell. 
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Figure  5.3 View of the hydrogen bonded network of complex (2a) in the unit cell 
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5.1.7 Computational analysis 
B3LYP optimized structure was analyzed computationally for complex [Au(en)2]
3+
 (1) 
using B3LYP/LanL2DZ level of theory which shows acceptable for the experimental 
values from the crystal structure of the gold(III) complex with ethylenediamine (en) [71]. 
Selected bond lengths and torsion angles of the computationally optimized structure are 
presented in Table 5.7 and Table 5.8 respectively. The computational results show that 
complex [Au(en)2]
3+
 (1), has a slightly distorted square planar geometry as shown in 
Figure 5.4. 
 
 
Figure 5.4 Computationally optimized structure of [Au(en)2]
3+ complex 
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Table 5.7 Selected bond lengths (Å) drived computationally for [Au(en)2]
3+ structure  
Bond Length (Å) 
Au-N (1) 2.1207 
Au-N (2) 2.1218 
Au-N (3) 2.1196 
Au-N (4) 2.1226 
 
Table 5.8 Selected torsion angles (º) drived computationally for [Au(en)2]
3+ structure  
Bonds Torsion angle (º) 
N(1)–Au–N(2) 82.287 
N(1)–Au–N(4) 97.714 
N(2)–Au–N(3) 97.7 
N(3)–Au–N(4) 82.299 
N(2)–Au–N(1)–C(2) -14.755 
N(4)–Au–N(1)–C(2) 165.246 
N(3)–Au–N(1)–C(2) 62.855 
Au–N(1)–C(2)–C(1) 41.005 
Au–N(2)–C(1)–C(2) 40.153 
 
  
69 
 
5.1.8 Effect of [Au(diamine)2]
3+
 complexes on cell proliferation 
The cytotoxicity assay was performed with complexes (1) and (4) on PC3 and SGC7901 
cells. The experimental PC3 and SGC7901 cells were treated with various concentrations 
of (1) and (4) for 24-72 hours and the cell viability was determined as described in the 
experimental section by MTT assay and the results are shown in Table 5.9 and in Figure 
5.5, Figure 5.6 and Figure 5.7.  
Figure 5.5 shows that cell proliferation of PC3 and SGC7901 cells was significantly 
reduced after 24 hrs of treatment with [Au(en)2]Cl3. From Figure 5.5, it is also quite clear 
that complex [Au(en)2]Cl3 (1), showed concentration dependent cytotoxic effect on 
cancerous cells PC3 and SGC7901. This observation is comparable with the report 
published by Milovanovic et al. on gold(III)-monoethylenediamine complexes on chronic 
lymphocytic leukemia (CLL) cells [105]. The same complex (1) was already found to 
exhibit relevant cytotoxicity properties when tested on human ovarian cancer cell lines 
i.e., A2780 and A2780 cis [37].  
Time dependent activity studies revealed that after 72 hr of the experiment with complex 
(1) on SGC7901 cell, the cell proliferation is bit higher than that of the PC3 cells at fixed 
10 μM concentration as shown in Figure 5.6. In Figure 5.7, the cytotoxicity results 
demonstrate that the complex (1) at 10 μM concentrations has higher cytotoxic effect in 
comparison with the same concentrations of complex (4). 
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Table 5.9 Effect of [Au(en)2]
3+complex on cell proliferation of gastric cancer cell line 
Compound Day 1 (24 hr) Day 3 (72 hr) 
Control 0.56  ± 0.03 1.30  ± 0.14 
[Au(en)2]Cl3 (1) 0.28  ± 0.03 0.45  ± 0.08 
 
 
 
 
Figure 5.5 Concentration dependent antiprolifrative effect of complex (1) on A) PC3 and B) SGC7901 cells 
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Figure 5.6 Time dependent antiprolifrative effect of complex 1 on (A) PC3 and (B) SGC7901 cells  
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Figure 5.7 Time dependent antiprolifrative effect of complex 1 on (A) PC3 and (B) SGC7901 cells 
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Figure 5.8 Time dependent antiprolifrative effect of complex 4 on (A) PC3 and (B) SGC7901 cells 
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5.1.9 in vitro Cytotoxicity of [Au(diamine)2]
+3
complexes (1-5) on prostate 
(PC3) and gastric (SCG7901) cancer cells 
The preliminary studies were reported on two gold(III) complexes, formulae [Au(en)2]Cl3 
(1) and [Au(N-pr-en)2]Cl3 (4) against prostate cancer cell lines (PC3) and gastric 
carcinoma cell lines (SGC7901). It is clearly observed that [Au(en)2]Cl3(1) has better 
anticancer activity than [Au(N-pr-en)2]Cl3(4) [93]. Casini et al. [106,133] have checked 
several gold(III) complexes for their cytotoxic effects against selected human cancer cell 
lines. They reported the in vitro cytotoxic properties of [Au(6-1,1-dimethylbenzyl)-2,2ʹ-
bipyridine)2] complex which indicated two fold higher activity as compared to cisplatin 
against A2780 ovarian cancer cells. 
The cytotoxic study was extended to a new series of gold(III) diamine complexes. A 
pioneer attempt was also made to evaluate in vitro cytotoxic effect of gold(III) diamine 
complexes against androgen-resistant prostate PC3 and human gastric SGC7901 cancer 
cells using MTT assay. The representative gold complexes (1) and (4) demonstrated a 
comparable cytotoxicity, as shown in Figure 5.7, whether the drug exposure was for 24, 
48 or 72 hr [93]. For that reason, we used a 3-day exposure protocol to assess IC50 value. 
Cisplatin was included for comparison.  
The IC50 data for Au(III) complexes (1-5) showed reasonable cytotoxicity in the  1-6 µM 
range for PC3 cells, as given in Table 5.10. For PC3 cells, complex (1) was recognized as 
effective cytotoxic agent like cisplatin while complexes (2-5) demonstrated about 4 to 6 
fold lower potency. Complexes (6-8) showed almost 7-9 fold lower cytotoxicity as 
compared to cisplatin. For SCG7901 cells, complexes (1-5 and 8) show slightly lower 
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cytotoxicity with respect to cisplatin whereas complexes (6-7) almost two fold more 
cytotoxic than cisplatin. Complexes (6-7) may be potential anticancer agents for cisplatin 
resistant SCG7910 cells. 
An independent assessment of complexes (1-5) reveals an interesting feature that 
SGC7901 gastric cancer cells exhibit 7 to 8 fold intrinsic resistance relative to the PC3 
cancer cells with respect to cisplatin. Nevertheless, only 2-fold or less resistance to 
complexes (2-5) was observed for PC3 as shown in Table 5.10. This suggests that the 
intrinsic factors regulating cellular sensitivity to cisplatin and complex (1) are different 
for PC3 and SGC7901 cells. The factors affecting sensitivity of PC3 and SGC7901 cells 
are analogous in complexes (2-5). There is no doubt that the present results in the study 
will be helpful for further exploiting and defining the potential role of gold(III) 
complexes in combat against prostate and gastric cancers. 
The inhibitory effect of complexes (2) to (5) on the proliferation of rapidly dividing cells 
may be attributed to the induction of cell cycle blockage, interruption of the cell mitotic 
cycle, apoptosis or necrosis. 
Even though the exact mechanisms on anti-proliferation of [Au(diamine)Cl2]Cl 
complexes remains vague, the inhibitory effect of complex (6-8) on the proliferation of 
rapidly dividing cancer cells may be attributed to the induction of cell cycle blockage, 
interruption of the cell mitotic cycle, apoptosis and necrosis. 
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Table 5.10 in-vitro Cytotoxicity of Au(III) diamine complexes on PC3 and SGC7901 cell lines 
Complex 
a
IC50 (M) Fold Resistance 
PC3 SGC7901 
SGC7901/PC3 
ratio 
Cisplatin 1.1 0.1 7.3 0.5 6.6 
(1) 1.0  0.1 8.5  0.6 8.5 
(2) 6.2  0.4 8.1  0.5 1.3 
(3) 4.2  0.3 9.5  0.1 2.3 
(4) 4.6  0.4 9.7  0.7 2.1 
(5) 6.8  0.4 9.6  0.1 1.4 
(8) 7.5  0.08 4.1  0.26 0.55 
(9) 9.3  0.10 3.3  0.07 0.35 
(10) 8.0  0.71 7.9  0.01 0.99 
a
IC50 data are given with ± SD.  
Each experiment was performed independently at least 3 times. 
5.1.10  Inhibitory effect of [(diamine)AuCl2]
1+ 
complexes (8-10) on prostate 
(PC3) and gastric (SGC7901) cancer cells 
All gold(III) complexes showed concentration dependent cytotoxic effect in cancer cell 
lines SGC7901 and PC3 as illustrated in Figure 5.9 to Figure 5.14.  
The cell proliferation of PC3 and SGC7901 cells is significantly reduced after 24 hrs of 
treatment with complex (8) as shown in Figure 5.9. This observation is consistent with 
the report published by Milovanovic et al. on gold(III)-monoethylenediamine complexes 
on chronic lymphocytic leukemia (CLL) cells [105]. The same compound was found to 
exhibit pertinent cytotoxic properties when tested in different human ovarian cancer cell 
lines A2780. The time dependent activity revealed that the cell proliferation on SGC7901 
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cells is slightly higher than that of the PC3 cells at fixed 10 M concentration after 72 hrs 
of the experiment with complex (9).  
The MTT results showed the effect of complexes (8-10) on prostate cancer cells growth, 
where the first two complexes (8) and (9) demonstrated inhibition in cancer cells growth 
in PC3, while the last complex (10) did not show any significant changes in cancer cells 
growth in PC3. Thus, complexes (8) and (9) might prove to be reasonably good 
candidates as anticancer drugs for prostate cancer.  
The MTT results also showed the effect of complexes (8-10) on gastric cells growth, 
where the first complexes (8) demonstrated inhibition in cancer cells growth in 
SGC7901, while the last two complexes (9) and (10) did not show any major changes in 
cancer cells growth in SGC7901. Thus, complex (10) might prove to be practically good 
candidate as anticancer drug for gastric cancer.  
Even though the exact mechanisms of anti-proliferation of [Au(diamine)Cl2]Cl 
complexes remains uncertain, the inhibitory effects of complexes (8-10) on the 
proliferation of rapidly dividing PC3 and SCG7901 cells may be accredited to the 
induction of cell cycle blockage, interruption of the cell mitotic cycle, apoptosis and 
necrosis [134–136]. 
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Figure 5.9 (A) Concentration dependent and (B) Time dependent inhibitory effect of complex 8 on PC3 cells 
growth 
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Figure 5.10 (A) Concentration dependent and (B) Time dependent inhibitory effect of complex 9 on PC3 cells 
growth 
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Figure 5.11 (A) Concentration dependent and (B) Time dependent inhibitory effect of complex 10 on PC3 cells 
growth 
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Figure 5.12 (A) Concentration dependent and (B) Time dependent inhibitory effect of complex 8 on SGC7901 
cells growth.  
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Figure 5.13 (A) Concentration dependent and (B) Time dependent inhibitory effect of complex 9 on SGC7901 
cells growth  
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Figure 5.14 (A) Concentration dependent and (B) Time dependent inhibitory effect of complex 10 on SGC79013 
cells growth  
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5.1.11  in vitro Cytotoxicity of Au(III) diamine complexes on ovarian cancer 
cell lines 
The in vitro cytotoxicity of Au(III) diamine complexes (1) and (8) was evaluated in terms 
of IC50 on cisplatin sensitive ovarian A2780 cancer cells and cisplatin resistant ovarian 
A2780 cis cancer cells. The IC50 (µM) data are shown in Table 5.11. The cisplatin-
resistant cell line A2780 cis is developed by chronic exposure of the parent cisplatin-
sensitive A2780 cell line. In order to retain resistance, 1.0 µM cisplatin needs to be added 
to the media for A2780 cis every 2-3 passages.  
IC50 data for cisplatin sensitive A2780 shows that [Au(en)2]Cl3 (1) and [Au(en)Cl2]Cl (8) 
with IC50 values 4.6 and 5.0 are three times less in vitro cytotoxic agent than that of 
cisplatin with IC50 value 1.5, whearas IC50 data for cisplatin resistant A2780 cis cancer 
cell line shows that [Au(en)2]Cl3 (1) is slightly stronger cytototoxic agent while 
[Au(en)Cl2]Cl (8) is slightly weaker cytotoxic agent  than cisplatin with IC50 value of 
12.8. Cisplatin has been included for comparison. Casini et al [29] also reported A2780 
and A2780 cis data for the complex (1), and these are in agreement with our study.  
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Table 5.11 in vitro Cytotoxicity of Au(III) diamine complexes on ovarian cell lines 
Complex 
a
IC50 Fold Resistance 
A2780 A2780 cis A2780 cis/A2780 
Cisplatin 1.5 ± 0.2 12.8 ± 0.5 8.4 
[Au(en)2]Cl3(1) 4.6 ±  0.3 10.6  ±  0.4 2.3 
[Au(en)Cl2]Cl3(8) 5.0  ± 0.3 14.3  ±  0.5 2.9 
a
IC50 data are given with ± SD. 
Each experiment was performed independently at least 3 times. 
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5.2 Gold(III) Complexes of Diamine and Thione Ligands 
This work reports the synthesis of some [(thione)2Au(diamine)]Cl3 complexes where 
thione = 1,3-imidazolidine-2-thione (Imt), 1,3-Diazinane-2-thione (Diaz) and diamine = 
diaminoethane (en), 1,3-diaminopropane (pn) or 1,4-diaminobutane (bn). 
5.2.1 Mid-IR characterization 
The selected mid-IR frequencies are given in Table 5.12. The vibrational frequency for 
thione ligands ν(C=S) shows red shift upon complexation as a result of electron donation 
from sulfur to the metal center that promote Π-back donation to thione Π* orbital, this 
causes weakening of the C-S bond [66]. On the other hand, the N-H vibrational 
frequency, ν(N-H), was found to shift to higher wave number (blue shift) indicating the 
strengthening of N-H bond in complex compared to the free ligand, as a result of electron 
donation form sulfur.  
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Table 5.12 Mid-IR frequencies, ν(cm-1) of Au(III) thione complexes 
Compound ν(N-H), cm
-1
 ν(C=S), cm
-1
 
Imt 3200 506 
[(Imt)2Au(en)]Cl3 (11) 3426 w 495 
[(Imt)2Au(pn)]Cl3 (12) 3426 s 497 
[(Imt)2Au(bn)]Cl3 (13) 3400 w 496 
Diaz 3166 516 
[(Diaz)2Au(en)]Cl3 (14) 3423 w 503 
[(Diaz)2Au(pn)]Cl3 (15) 3444 m 505 
[(Diaz)2Au(bn)]Cl3 (16) 3413 sh 506 
Diap 3143 519 
[(Diap)2Au(en)]Cl (17) 3418 m 507 
[(Diap)2Au(pn)]Cl (18) 3428 m 509 
 
5.2.2 Solution state NMR characterization 
The 
13
C NMR chemical shifts of thione and their complexes are given in Table 5.13. In 
13
C resonances at 182.11 and 45.38 ppm correspond to S=C< (free Imt) and C-CH2-NH 
(free Imt) respectively. The upfield chemical shift for S=C< carbon of Imt from 182.1 to 
about 175.8 ppm accounts for coordination of sulphur atom of of S=C< towards Au(III) 
centre. Chemical shifts at 173.34, 41.20 and 19.07 ppm correspond to S=C<, CH2-NH 
and C-CH2-C carbon atoms of free Diaz respectively. The larger upfield chemical shift 
for carbon of S=C< (bound Diaz) from 173.34 to about 166.51 ppm is consistent the 
ligation of sulfur of S=C< towards Au(III) center [137].  The smaller upfield shifts of C-
CH2-NH (bound Diaz) and C-CH2-C (bound Diaz) also corroborates the binding of 
carbon of S=C< (bound Diaz) to Au(III). The evident upfield shift of carbon of S=C< 
bound thione in [(thione)2Au(diamine)]Cl3 with respect to free thiones indicates 
coordination of thiones through sulphur of S=C<  to Au(III) centre as shown in Table 
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5.13. The
 1
H NMR spectra for [(thione)2Au(diamine)]Cl3 complexes are very 
complicated because of the strained structures of diamine ligands and non-equivalency of 
hydrogen environments  in the complexes [138]. 
1
H NMR data were, therefore, found to 
be non-descriptive for such complexes.  
Table 5.13  Solution state13C chemical shifts (ppm) for Au(III) thione complexes 
Compound S=C<(Imt) C-CH2-NH(Imt)     
Free Imt 182.11 45.38 
  
[(Imt)2Au(en)]Cl3 (11) 175.73 45.1 
  
[(Imt)2Au(pn)]Cl3 (12) 175.93 45.06   
[(Imt)2Au(bn)]Cl3 (13) 175.94 45.06     
 
S=C<(Diaz) C-CH2-NH(Diaz) C-CH2-C(Diaz)   
Free Diaz 173.34 41.2 19.07 
 
[(Diaz)2Au(en)]Cl3 (14) 166.56 36.68 18.42  
[(Diaz)2Au(pn)]Cl3 (15) 166.59 36.33 18.42  
[(Diaz)2Au(bn)]Cl3 (16) 166.51 38.38 18.4   
 
S=C<(Diap) C-CH2-NH(Diap) C-CH2-C(Diap) C-CH2-C(Diap) 
Free Diap 163.34 40.13 18.34 16.07 
[(Diap)2Au(en)]Cl3 (17) 159.23 37.13 18.01 15.79 
[(Diap)2Au(pn)]Cl3 (18) 159.02 36.43 17.91 15.67 
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5.2.3 Solid state NMR characterization  
The Solid state NMR data for the complexes are given in Table 5.14. The thiocarbonyl 
resonances in the ligands Imt and Diaz, appear at 180.6 and 175.6 ppm respectively 
[139]. So it can be seen that thiocarbonyl carbons are de-shielded by about 12 to 17 ppm 
relative to the free ligand, confirming the coordination through the sulfur atom of the 
thione group. The high values of 
15
N chemical shifts are assigned to Imt and Diaz 
nitrogens, whereas the low value of 
15
N chemical shift is assigned to the diamine ligands. 
The 
15
N shifts of the diamines in the complexes show lower shifts of 5-17 ppm, compared 
to that in the free ligands. These shifts indicate an increase in electron density at the 
nitrogen atom, in agreement with literature [138]. 
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Table 5.14 Solid state 13C and 15N NMR chemical shifts of Au(III) thione complexes 
Complex Nucleus δiso σ11 σ22 σ33 Span Skew Other 
(11) 
13
C 155.41 
     
46.78 
 
15
N -260.14, -335.83 
      
(12) 
13
C 177.03 257 183 90 167 0.116 46.58 
 
 13
C 154.9 221 163 81 139 0.175 
 
 
15
N -258.2 
      
(13) 
13
C 176.93 252 193 86 167 0.289 46.29 
 
15
N -259.6 
      
(14) 
13
C 166.74 241 186 73 168 0.351 42.70, 19.41 
 
13
C 149.37 223 143 82 141 -0.127 
 
 
15
N -357.6 
      
(15) 
13
C 167.31 
     
43.48, 19.50 
 
15
N -337.47 
      
(16) 
13
C 171.69 244 189 83 161 0.319 44.74, 27.46 
  
15
N -205.2             
a
Isotropic shielding, σiso = (σ11 + σ22 + σ33 )/3 
Δ σ = σ33 – 0.5(σ11 + σ22) 
bη = 3( σ22 - σ11 ) / 2Δσ 
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5.2.4 Computational analysis 
Built and optimized structures were analyzed computationally for vibrational frequencies 
and NMR data using B3LYP/LanL2DZ level of theory, to facilitate the spectroscopic 
data interpretation. Selected bond length and torsion angles of the computationally 
optimized structures are presented in Table 5.15 and Table 5.16 respectively. 
Comparisons of calculated bond lengths show that the C-S bond of thione becomes 
longer after complexation due to Π-back donation; this agrees with the experimental mid-
IR data that shows red shift upon complexation.  
Additionally, C-S bonds were longer in Diaz complexes compared to C-S bond length in 
Imt complexes. It is obviously an indication of larger Π-back donation as well as stronger 
bond in Diaz complexes. In general, this observation agrees also with the higher up-field 
shift effect on Diaz C-S carbon as detected by 13C NMR, which clarify the higher back 
donation in Diaz complexes. After optimization, the built complexes showed square 
planar structures around the gold(III) center; S-Au-N angles were ranging from 173o to 
179o. Optimized geometries of [(thione)2Au(diamine)]Cl3 complexes (11-16) at the 
B3LYP/LanL2DZ level of theory using Gaussian 09, Revision A. 1 are shown in  
Figure 5.15. 
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Table 5.15 Selected bond lengths (Å) drived computationally for (thione)2Au(diamine)]
3+ structures 
Bond [(Imt)2Au(en)]
3+
 [(Imt)2Au(pn)]
3+
 [(Imt)2Au(bn)]
3+
 [(Diaz)2Au(en)]
3+
 [(Diaz)2Au(pn)]
3+
 [(Diaz)2Au(bn)]
3+
 
Au-N1 2.163 2.159 2.157 2.167 2.174 2.177 
Au-N2 2.173 2.171 2.157 2.167 2.164 2.156 
Au-S1 2.473 2.483 2.493 2.474 2.481 2.482 
Au-S2 2.471 2.482 2.493 2.474 2.477 2.480 
S1-C 1.825 1.824 1.829 1.859 1.851 1.851 
S2-C 1.824 1.823 1.829 1.859 1.851 1.852 
 
Table 5.16 Selected torsion angle (°) drived computationally for [(thione)2Au(diamine)]
3+ structures 
Angle [(Imt)2Au(en)]
3+
 [(Imt)2Au(pn)]
3+
 [(Imt)2Au(bn)]
3+
 [(Diaz)2Au(en)]
3+
 [(Diaz)2Au(pn)]
3+
 [(Diaz)2Au(bn)]
3+
 
S1-Au-N1 93.87 89.37 86.79 93.24 87.37 86.79 
S2-Au-N2 91.93 87.43 86.79 93.23 90.20 86.79 
N1-Au-N2 81.81 90.71 94.40 81.84 90.73 94.40 
S1-Au-S2 92.53 92.66 92.18 91.89 91.76 88.35 
S1-Au-N2 174.55 176.96 176.75 173.98 176.16 176.10 
S2-Au-N1 173.15 176.16 176.76 173.98 176.96 177.07 
Au-S1-C 106.76 107.14 108.57 108.65 110.14 109.41 
Au-S2-C 110.77 111.74 108.57 108.66 110.14 109.47 
 
  
93 
 
 
 
Figure 5.15 Computationally optimized structures of [(thione)2Au(diamine)]
3+ complexes  
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5.2.5 in vitro Cytotoxicity of Au(III) thione complexes 
The EAE (Experimental Autoimmune Encephalomyelitis) was evaluated for its 
antiproliferative effect using MTT assay. The [(thione)2Au(diamine)]Cl3 complexes 
inhibited the proliferation of C6 glioma cells in a concentration dependent manner. IC50 
values were calculated from the growth curve using MTT assay (Figure 5.16). It showed 
values of inhibition 42, 36, 73, 152, 62, 61 μg/mL for [(thione)2Au(diamine)]Cl3 
complexes 11, 12, 13, 14, 15 and 16 respectively. Therefore, the 
[(thione)2Au(diamine)]Cl3 complexes 11, 12, 15 and 16 were more effective for the C6 
glioma cells.  
It is evident from IC50 values that Imt containing Au(III) complexes (11-13) are relatively 
better cytotoxic agents than Diaz containing Au(III) complexes (14-16). As far as 
cytotoxicity against C6 glioma cells is concerned, the five member thione ring (Imt) is 
fairly better ligand than the six member thione ring (Diaz). However, the six member 
Au(III) chelates (12 and 15) with 1,3-Diaminopropane (pn) are comparatively better 
cytotoxic agents than five member chelate (1 and 4) with 1, 2-diaminoethane (en) as well 
as seven member chelate (13 and 16) with 1,4-diaminobutane (bn). It can be concluded 
that structural features e.g. ring size of thione ligand (Imt and Diaz) as well as Au(III) 
chelate size with diamine (en, pn and bn) may affect in vitro cytotoxicity of complex 
against C6 glioma cell line. 
The MTT results based on phase contrast micrographs showed a decrease in cell density 
on treatment with different concentrations of extract. Significant numbers of cells were 
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found to be round, detached and floating at higher concentrations and the samples were 
photographed after removing dead floating cells to improve the quality of images.  
Even though the anticancer efficacy of imidazolidine-2-thione (Imt) and ethylenediamine 
(en) of [(thione)2Au(diamine)]Cl3 complexes has independently been reported, so far their 
chemotherapeutic potential as a combined complex has not been analyzed.  
The Imidazolidine-2-thione (Imt) containing complexes [(Imt)2Au(en)]Cl3 (11) and 
[(Imt)2Au(pn)]Cl3 (12) showed toxicity profiles comparable to cisplatin [140] which has 
been documented to have an overall IC50 in the range of 10.9-67.0 µM. Yildrim et al. 
reported the IC50 data of some anticancer compounds specifically against glioma C6 cell 
lines [141]. They tested anti-proliferative activity of novel platinum compounds against 
C6 glioma cells and demonstrated an IC50 range of 16.75-28.75 µg/mL with respect to 
cisplatin. Comparison with other gold(III) compounds has scarcely been studied. 
Pivetta et al. analyzed the role of imidazolidine-2-thione as an anticancer agent in 
combination with other metal ions [142]. They found a high in vitro cytotoxicity of 
imidazolidine-2-thione copper (II) complexes in mouse neuroblastoma N2a cells. 
Imidazolidine influences apoptosis, a mechanism of programmed cell death functioning 
to eliminate damaged, mutated or cancerous cells. Chemotherapeutic agents cause 
simultaneous activation of apoptotic signals and induction of anti-apoptotic factors, such 
as NF-kappa B and subsequently diminish the overall efficacy of the administered drug. 
Sharma et al. [143,144] described imidazoline to modulate the NF-kappa B pathway by 
preventing its nuclear translocation and selectively sensitizing the cancer cells toward 
DNA damaging agent. The pretreatment of cancer cells with the imidazoline causes a 
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significant increase in apoptosis resulting in augmented efficacy of camptothecin and 
cisplatin. Comparative studies are required to interpret the functional advantages of alkyl 
substituted thiones and to establish structure-activity relationship (SAR) using different 
ring size of thiones (Imt, Diaz and Diap) incorporation in the gold(III) complexes. 
 
Figure 5.16 in vitro Cytotoxicity of Au(III) thione complexes on C6 glioma cell line 
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5.3 Cyanido(diamine)Mercury(II) complexes 
This work reports the synthesis and characterization of some Hg(II) diamine complexes 
with general formula [(diamine)Hg(II)(cyanido)2] where cyanido = CN
-
 and diamine = 
en, pn, N-Me-en, N,N'-Me2-en, N,N'-Et2-en and N,N'-ipr2-en. 
5.3.1 Mid-IR Studies  
Selected mid-IR bands for the free ligands, Hg(II) precursor and the prepared complexes 
are given in Table 5.17. A sharp band around 3300 cm
–1
 was observed for all the 
complexes indicating the presence of diamines. The C≡N stretching frequency of 
Hg(CN)2 is observed at 2191 cm
-1
. For all prepared complexes (19-24), only one ν(C≡N) 
mode was observed, at lower frequency compared to the free Hg(CN)2. For example, in 
case of the complex (19), the ν(C≡N) shift appears about 33 cm-1 towards lower 
frequency  than that of the cyanide precursor. This is consistent with a significant back 
donation of electron density from the metal to the empty * orbitals of cyanide upon 
coordination to the diamines. The changes in ν(N–H) between ligands and corresponding 
complexes are small and within experimental error. 
In comparison to other mercury complexes previously reported by our group, it is clear 
that the reaction between amines and Hg(CN)2 is more favorable than with Hg(SCN)2 
and Hg(SeCN)2 because the signals at CN region for all complexes are obtained 
[100,102]. This shows that the Hg(CN)2 complex is the most stable, while the Hg(SCN)2 
and Hg(SeCN)2 complex is least stable with some exceptions. In a similar point of view, 
in the case of d
10
 metals, a comparison of the shift differences in C≡N region for 
Zn(CN)2, Cd(CN)2 and Hg(CN)2 are worthy enough to mention. It is observed that the 
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shift difference is greater for Zn(II) complexes and less for Hg(II) and Cd(II) complexes 
[103,145]. This suggests that cyanide forms more stable complexes with Zn(II) than with 
Hg(II) and Cd(II). 
Table 5.17 Mid-IR data of Hg(II)(CN)2-diamine complexes 
Compound ν(N-H) ν(C-N)  ν(C≡N)  
Hg(CN)2 --- --- 2191 
en 3393 1033 --- 
[(en)Hg(CN)2] (19) 3378 1571 2158 
pn 3282 1093 --- 
[(pn)Hg(CN)2] (20) 3280 1558 2154 
N-Me-en 3282 1130 --- 
[(N-Me-en)Hg(CN)2] (21) 3294 1590 2166 
N,N'-Me2-en 3288 1148 w, 1103 m --- 
[(N, Nʹ-Me-en)Hg(CN)2] (22) 3253 1454 2169 
N,N'-Et2-en 3235 1125 --- 
[(N, Nʹ-Et-en)Hg(CN)2] (23) 3245 1448 2166 
N,N'-ipr2-en 3249 1173 --- 
[(N, Nʹ-iPr-en)Hg(CN)2] (24) 3247 1495 2168 
 
5.3.2 Solution state NMR studies 
The 
13
C and 
15
N NMR chemical shifts of various complexes are summarized in Table 
5.18 and Table 5.19 respectively. In all prepared complexes, upfield 
13
C NMR chemical 
shifts were observed with respect to the free ligands. Similar to the polymeric [bn-
Hg(CN)2] complex, the 
13
C NMR spectrum of [en-Hg(CN)2] shows no significant shift in 
the cyanide signal upon complexation with en ligand, while a downfield shift of around 3 
ppm was observed for the en ligand carbons. This shift may be due to the flow of electron 
density from C to N, in the complexes [98,103,146–149]. 
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On the other hand, the 
15
N NMR signal of complex 2 is shifted downfield compared that 
of the free ligand, 1,3-diaminopropane (pn). However, no significant shift difference was 
observed between the complexes. For example, 
15
N NMR chemical shift of 
ethylenediamine ring nitrogens in complexes (22 and 24) is very similar to that of the 
propylenediamine ring in complex (20). 
The 
13
C and 
15
N NMR chemical shifts of various complexes are summarized in Table 
5.18 and Table 5.19 respectively.  With few exceptions, upfield 
13
C NMR chemical shifts 
were observed with respect to the free ligands. Similar to the polymeric [bn-Hg(CN)2] 
[150], the 
13
C NMR spectrum of [en-Hg(CN)2] shows shift in cyanide signal upon 
complexation with en, while a downfield shift of around 3 ppm was observed for the 
ethylenediamine (en) carbons. This shift may be due to the flow of electron density from 
C to N, in the complexes [98,146,147,149]. The 
15
N NMR signal of complex (20) is 
shifted upfield compared to that of pn·HCl. However, shift difference was observed 
between the complexes. For example, 
15
N NMR chemical shift of ethylenediamine ring 
nitrogen atoms in complexes (22 and 24) is very similar to that of the propylenediamine 
ring in complex (20). 
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Table 5.18 13C NMR chemical shifts of Hg(CN)2-diamine complexes  
Compound 
13
C-N C-1 C-2 C-3 
Hg(CN)2 145.15    
en 
 
45.05 
  
[(en)Hg(CN)2] (19) 144.24 42.12   
pn 
 
39.86 37.33 
 
[(pn)Hg(CN)2] (20) 143.28 38.02 35.45  
N-Me-en 
 
36.26 46.37 
 
[(N-Me-en)Hg(CN)2] (21) 144.42 41.48 31.26  
N, N'-Me2-en 
 
51.43 36.49 
 
[(N, N'-Me2-en)Hg(CN)2] (22) 143.28 50.17 35.99 
 
N, N'-ipr2-en  
48.82 47.57 23.09 
[(N, N'-ipr2-en)Hg(CN)2] (24) 143.46 49.03 47.11 22.21 
 
Table 5.19 15N NMR chemical shifts of Hg(CN)2-diamine complexes  
Compound 
15N (δ in ppm) 
pn•HCl -343.12 
[(pn)Hg(CN)2] (20) -363.52 
[(N, N'-Me2-en)Hg(CN)2] (22) -363.19 
[(N, N'-ipr2-en)Hg(CN)2] (24) -362.34 
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5.3.3 Solid state CPMAS NMR characterization 
Table 5.20 shows Solid state NMR data for the complexes studied. 
199
Hg signals in the 
complexes are almost 1000 ppm de-shielded from those in Hg(CN)2, with the change in 
geometry and coordination of two nitrogen atoms to 
199
Hg (Figure 5.17 and Figure 5.18). 
This is a clear confirmation that the complexes are formed. As reported for some mercury 
cyanide/chloride double salts, these complexes have a see-saw effective coordination 
geometry based upon characteristic linear coordination [151]. The C–Hg–C bond angles 
in their complexes are the range 150–160 º. The Hg anisotropies are 2300–3400 ppm in 
our earlier studies [100] on Hg(CN)2 complexes with imidazolidine-2-thiones and its 
derivatives, the anisotropies of 
199
Hg (1400–2000 ppm) have been rationalized in terms 
of stronger coordination of sulfur compared to chloride, making the C–Hg–C angle less 
than 150 º; that is closer to a highly distorted tetrahedral geometry. The computed C–Hg–
C bond angle for (19) described here is 157.89 º and the diamine is weakly coordinated. 
So, the 
199
Hg anisotropies in the complexes under study here are 1000 ppm, perhaps 
indicating weaker binding of diamines to Hg(CN)2; that is also indicated by the 
calculated structural parameters. 
13
C and 
15
N CPMAS spectra show two distinct 
resonances for CN for complexes (23, 22 and 24) as shown in Figure 5.19, Figure 5.20 
and Figure 5.21 respectively, indicating two chemically different environments for CN. 
This suggests that two distinct molecules may exist in a unit cell, or one CN is H-bonded 
and the other is free. The nitrogen resonances in CN show skew values of 1.00 indicating 
that axial symmetry is maintained, whereas the carbon resonances show skew values less 
than 1.00. The 
15
N signals from –NH2 or NH is slightly overlapped with CN side bands 
and we can only pick out one type of resonance for this nucleus. 
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Table 5.20 Solid state 13C, 15N and 199Hg isotropic chemical shifts (δiso) and principle shielding tensors (σxx ) of 
Hg(II) cyanide complexes with diamines 
Complex Nucleus δiso σ11 σ22 σ33 Ω (Span
a
) κ (Skewb) 
[Hg(CN)2] 
  13
C(CN) --- 
          
  119
Hg -1396 
(19) 
13
C(CN) 163.7 282.22 192.84 13.94 267 0.6 
15
N -125.2 
     
15
N(en) -315.5 
     
199
Hg -503 30.79 -555.35 -985.61 1016 0.805 
(22) 
i) 
13
C(CN) 145.3 291.9 207.7 -63.7 355.6 0.53 
ii) 
3
C(CN) 143.5 274.8 235.8 -80.1 354.9 0.78 
i)
15
N(CN) -92.5 110.3 110.3 -498.3 608.3 1 
ii)
15
N(CN) -95.9 101.1 101.1 -489.9 590.9 1 
    
 15
N(en) -348.5 
     
   119
Hg -311.5           
(23) 
i)
13
C(CN) 142.9 214.5 214.5 -0.39 214.9 1 
ii)
13
C(CN) 145.8 217.4 217.4 2.5 214.9 1 
i)
 119
Hg -365.7 157.5 -306.9 -947.7 1105.2 0.16 
ii)
 119
Hg -371.6 159.5 -332.5 -942 1101.5 0.11 
(24) 
13
C(CN) 146.5 249.1 249.1 -58.7 307.9 1 
15
N(CN) -91.9 72.7 72.7 -421 493.7 1 
 15
N(en) -316.3      
    119
Hg -504.3 -29.4 -408.6 -1074.4 1045.4 0.28 
a
 Isotropic shielding, σiso = (σ11 + σ22 + σ33 )/3 
Δ σ = σ33 – 0.5(σ11 + σ22) 
bη = 3( σ22 - σ11 ) / 2Δσ 
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Figure 5.17 199Hg CPMAS spectrum of (23).  
 
Figure 5.18 199Hg CPMAS spectrum of (24). 
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Figure 5.19 13C CPMAS spectrum of (23). 
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Figure 5.20 (a) 15N and (b) 13C CPMAS spectra of (22) 
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Figure 5.21 (a) 15N and (b) 13C CPMAS spectra of (24). 
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5.3.4 Computational analysis 
The computationally optimized structures of 19 and 20 are shown in Figure 5.22. The 
selected bond lengths and bond angles of the optimized structures are presented in Table 
5.21 and Table 5.22 respectively. In both complexes, Hg atom exhibits a severly distorted 
tetrahedral geometry completed by the two N atoms of diamines and two C atoms of the 
cyanide groups. The Hg-N and Hg-C bond distances and most of the bond angle values 
are in agreement with those observed in other reported complexes [150,152–154]. 
 In both 19 and 20, the Hg-C distance is slightly longer than that in the structure of 
Hg(CN)2 (2.015(3) Ǻ) [48]. The C-Hg-C angles in 19 and 20 are 157.89
o
 and 156.36º 
respectively, which are much larger than the normal tetrahedral value of 109.5
o
. These 
large angles are counter balanced by the very small N-Hg-N bond angles of 72.20
o
 and 
81.06
o
 for 19 and 20 respectively. This tetrahedral distortion as well as somewhat longer 
Hg-N distances than those in [Hg(CN)2-bn]n indicate a weak binding of diamine ligands 
to Hg(II). The C-Hg-N bond angles in 19 and 20 are 97.45 and 100.91 respectively. In 
comparison to bn (1,4-diaminobutane), which formed a linear polymeric complex 
[Hg(CN)2-bn]n, the diamines used in this study, en and pn are found to form chelates, 19 
and 20. As indicated by the N-Hg-N bong angles, the chelate formed by pn is less 
strained than that of en. 
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Figure 5.22 Computationally optimized structure of complexes (25 and 26) 
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Table 5.21 Selected bond lengths derived computationally for 19 and 20 complexes 
Complex Bond Length (Å) 
 
C≡N 1.189 
 
Hg-C 2.208 
19 Hg-N 2.59 
 
C-N 1.496 
  C-C 1.541 
 
C≡N 1.189 
 
Hg-C4 2.211 
 
Hg-C5 2.218 
20 Hg-N1 2.568 
 
Hg-N2 2.568 
 
C1-N2 1.498 
 
C3-N1 1.498 
  C1-C2 1.544 
 
Table 5.22 Selected bond angles derived computationally for 19 and 20 complexes 
Complex Bonds Angle (
o
) 
 
Hg-C≡N 175.53 
 
C-Hg-C 157.89 
19 C1-Hg-N1 97.45 
 
C2-Hg-N1 100.5 
 
C-N-Hg 106.87 
  N-Hg-N 72.2 
 
Hg-C4-N3 176.43 
 
C4-Hg-C5 156.36 
 
C4-Hg-N1 100.92 
20 C2-Hg-N2 100.92 
 
C1-N2-Hg 112.37 
 
C3-N1-Hg 112.38 
  N1-Hg-N2 81.07 
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5.3.5 Bioactivity studies 
The antibacterial activities of Hg(CN)2 and two of its complexes estimated by minimum 
inhibitory concentrations (MIC; μg mL-1) are given in Table 5.23. The results show that 
the complex 19 in DMSO is particularly effective in inhibiting the growth of tested 
bacteria. The compound 20 although shows some activity against two of the microbes, in 
general, it was found to be highly resistant against all four bacteria. A comparison 
between the activity of 19 and 20 against the most sensitive organism, E. coli shows that 
the minimum concentration increased from 775 to 930 μg/mL in water and 720 to 950 
μg/mL in DMSO as we move from 19 to 20. The greater activity of 19 may be related to 
its less stability originated from a more strained ring of the chelate so that the ligand 
could be easily replaced by biological ligands. 
Table 5.23 Antibacterial activities of Hg(II)(CN)2-diamine complexes 
Test organism 
Hg(CN)2 Hg(CN)2 19 19 20 20 
in water in DMSO in water in DMSO in water in DMSO 
HPC >1000 950 850 825 >1000 >1000 
P. Aeruginosa 950 900 800 750 >1000 >1000 
F. Streptococcus >1000 >1000 800 750 975 940 
E. Coli 850 800 775 720 930 950 
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5.4 Cadium(II) and Mercury(II) Selenocyanate Complexes 
This work reports the synthesis and characterization of some Cd(II) and Hg(II) 
selenocyanate complexes with general formula [(L)M(II)(selenocyanate)2] where 
selenocyanate = SeCN
-
; M(II) = Cd(II) or Hg(II) and L=Gly or His. 
5.4.1 Mid-IR studies  
The C≡N stretching frequency for Hg(SeCN)2 is higher than that of Cd(SeCN)2. It means 
that C-N bond in Hg(SeCN)2 is relatively stronger than that in Cd(SeCN)2. It is because of 
less electron density at the selenium atom that derives more π-back donation from Hg to 
Se. In Table 5.24, the mid-IR data shows highest red shift for selenocyanate stretching 
frequency for histidine complex of mercury. It means that there is the highest π-back 
donation from the metal to the selenocyanate in histidine complex owing to the greater 
donation to the anti-bonding π-orbitals of the cyanate from selenium atom. It is clearly an 
indication of stronger histidine mercury bonding than that of the rest of the complexes 
series.  
In general, there is a good agreement of the experimental and theoretical mid-IR 
stretching bands observed for the prepared complexes with some blue shift of the 
calculated results due to the intermolecular interaction in the real mid-IR experiment.  
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Table 5.24 Mid-IR frequencies, ν(cm-1) M(SeCN)2 complexes with Gly and His 
Compound 
ν(C=O) ν(C=O) SeCN SeCN  
Exp. Theo. Exp. Theo. Exp. Theo. 
KSeCN - - 2070
a
 - - - 
L-Gly 1606 s - - - 3424 - 
L-Hist 1634 s - - - 3127 - 
Cd(SeCN)2 - - 2107 - - - 
[(L-Gly)Cd(SeCN)2] (25) 1611 s 1759 2107 2127 3450 3455 
[(L-Hist)Cd(SeCN)2] (26) 1631 s 1718 2109 2112 3460 3402 
Hg(SeCN)2 - - 2127 - - - 
[(L-Gly)Hg(SeCN)2] (27) 1611 s 1742 2130 2137 3447 3476 
[(L-Hist)Hg(SeCN)2] (28) 1636 s 1716 2111 2118 3422 3423 
a
Published Paper [155]  
  
113 
 
5.4.2 Solution state NMR studies 
The 
13
C solution NMR data of all complexes are shown in Table 5.25. Downfield 
chemical shifts were observed for the prepared complexes: (Gly)Cd(SeCN)2 at 194.9 ppm 
and (Gly)Hg(SeCN)2 at 189.24 ppm with respect to the free ligand, glycine at 173.1 ppm. 
These high downfield shifts resulted from the electron donation from glycine carboxylate 
to metal thereby causing about 20 ppm shifts of carbonyl carbon, while this shift was not 
observed in the histidine complexes because in this case, imidazole nitrogen and α-amine 
are involved in coordination to the metal center, which agrees with the reported binding 
mode of histidine to mercury metal ion [156]. 
The decrease in electron density observed by downfield shift for the de-shielded Se 
bound to Hg (-109 ppm) compared with Se bound to Cd (-272 ppm) as shown by 
77
Se 
NMR (Table 5.26). In the case of histidine complexes of Hg(SeCN)2, the selenium atom 
becomes more shielded and shifted up-field (-169.71 ppm) because the donation from 
histidine to the metal center, which causes even stronger π-back donation to selenium. 
The
 77
Se NMR data clearly showed greater deshielding effect at the selenium via 
complexing to histidine, which bind through two nitrogen atoms [157]. 
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Table 5.25 13C NMR data for Hg(SeCN)2 and Cd(SeCN)2 with Gly and His 
Compound SeCN C=O C-1 C-2 C-3 C-4 C-5 
His - 174.7 136.2 135 117.9 55.1 29 
Gly - 173.1 42.5 
    
[Cd(SeCN)2] 116.9       
[(His)Cd(SeCN)2] (25) 115.4 173 136.6 134.5 117 53.5 28.1 
[(Gly)Cd(SeCN)2] (26) 119 194.9      
[Hg(SeCN)2] 103.3 
      
[(His)Hg(SeCN)2] (27) 109.8 170.3 135 132.3 116.4 53.3 27.4 
[(Gly)Hg(SeCN)2] (28) 116.5 189.2           
 
 
Table 5.26 77Se NMR data for Cd(SeCN)2, Hg(SeCN)2, and complex 27 
Compound 
77
Se (ppm) 
Cd(SeCN)2 -272.94 
Hg(SeCN)2 -109.18 
[(His)Hg(SeCN)2] (27) -169.71 
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5.4.3 Solid state CPMAS NMR 
The solid state CPMAS NMR spectral data for complexes (Gly)Cd(SeCN)2 and 
(His)Cd(SeCN)2 for 
13
C and (Gly)Hg(SeCN)2 and (His)Hg(SeCN)2 for 
15
N are shown in 
Table 5.27and Table 5.28 respectively. The solid state 
13
C and 
15
N NMR spectra are 
shown in Figure 5.23 and Figure 5.24 respectively. The corresponding peaks are denoted 
by asterisk. The calculated chemical shift tensors are also compiled in Table 5.27 and 
Table 5.28, along with the span, Ω, which describes the breadth of the chemical shift 
tensor and skew, κ, describing the shape of the powder pattern. From Table 5.27, solid 
state 
13
C NMR of glycine and histidine cadmium complexes show an increase in the 
chemical shift of the Se
13
CN (~2 ppm) for mercury (II) complex because the involvement 
of selenium in binding to the metal center, causing deshielding at the SeCN carbon. But 
in the case of the 
15
N NMR data in Table 5.28, histidine and glycine complexes show a 
significant downfield shift of the nitrogen atom signal of the amine group. Additionally, 
histidine shows downfield shift for the imidazole moiety, which facilitates the 
involvement of imidazole nitrogen in binding to metal. 
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Table 5.27 Solid state 13C Isotropic Chemical Shifts (δiso) and principle shielding tensors (σxx)
 a of Cd(II)-
Selenocyanate complexes with Gly and His  
Compound Nucleus δiso σ11 σ22 σ33 Δ σ 
bη 
Cd(SeCN)2 
113
Cd 211.9 322 283 30 291 0.73 
77
Se -119.6 53 41 -452 505 0.96 
13
C 117 222 205 -76 298 0.89 
[(Gly)Cd(SeCN)2] (25) 
13
C 170.8 242 171 98 -109 0.98 
13
C 119.9 212 124 23 -146 0.9 
[(His)Cd(SeCN)2] (26) 
13
C 169.3 236 169 102 -101 0.99 
13
C 108.4 181 103 41 -101 0.86 
13
C 132 202 136 58 -111 0.9 
13
C 129.2 196 130 61 -102 0.96 
13
C 119.5 213 120 23 -142 0.97 
a.
isotropic shielding,σiso = (σ11 + σ22 + σ33 )/3 
Δ σ = σ33 – 0.5(σ11 + σ22) 
bη = 3( σ22 - σ11 ) / 2Δ σ 
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Table 5.28 Solid state 15N isotropic chemical shifts (δiso) and principle shielding tensors (σxx)
 a of Hg(II)-
selenocyanate complexes with Gly and His  
Compound 
Nucleus δiso δ11 δ22 δ33 Δ σ η
b 
His 
15
N -202.55 -97.76 -181 -328.85 
-189.45 - 0.66 - 
15
N -331.02 - - - 
[(His)Hg(SeCN)2] (27) 
15
N -156.73 -27.66 
-169.72 
-272.8 -174.11 0.8 
15
N -146.5 - - - - 
Gly 
15
N -345.56 - - - - - 
[(Gly)Hg(SeCN)2] (28) 
15
N -311.01 - - - - - 
a.
isotropic shielding,σiso = (σ11 + σ22 + σ33 )/3 
Δ σ = σ33 – 0.5(σ11 + σ22) 
ηb = 3( σ22 - σ11 ) / 2Δ σ 
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Figure 5.23 13C CPMAS spectra of (a) (Gly)Cd(SeCN)2 and (b) (His)Cd(SeCN)2 
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Figure 5.24 15N NMR spectra of (a) (Gly)Hg(SeCN)2 and (b) (His)Hg(SeCN)2 
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5.4.4 Computational analysis 
Computational study shows that Glycine (C=O) and (C-O) bonds in the optimized 
structure (Figure 5.25) are shorter in Cd complex than in Hg complex (Table 5.29 and 
Table 5.30), which agrees with experimental 
13
C NMR results, while no difference in 
(C=O) and (C-O) bonds were observed in Histidine complexes indicating less 
contribution of carboxylate in binding. Se-Cd is shorter than Se-Hg because of the 
proximity in the atomic sizes of Se and Cd. It is worth-mentioning here that the 
calculated bond lengths are comparable to the reported experimental bond length for Se-
Cd obtained by single crystals (2.723 and 2.828 Å) [158,159]. It is also observed that Hg-
N and Hg-O is longer than Cd-N and Cd-O because Cd is harder than Hg, leading to 
better interaction. This may cause higher stability of Cd complexes in general. Nitrogen 
is less electronegative atom than oxygen so it can donate electron more easily to the 
metal and forms stronger bonds with metals, which results in stronger chelation through 
two nitrogens than chelation through nitrogen and oxygen. L-Histidine complexes of Hg 
and Cd have shorter bonds than Glycine complexes indicating stronger bonding of 
Histidine to theses metals. This agrees with the higher electron donation indicated from 
77
Se NMR data.  
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Table 5.29 Bond lengths (Å) derived computationlly for [LM(SeCN)2] structures  
Hg(SeCN)2 + His Cd(SeCN)2 + His Hg(SeCN)2 + Gly Cd(SeCN)2 + Gly 
Hg-Se1 2.765 Cd-Se1 2.718 Hg-Se1 2.699 Cd-Se1 2.656 
Hg-Se2 2.795 Cd-Se2 2.745 Hg-Se2 2.731 Cd-Se2 2.691 
Hg-N1 2.434 Cd-N1 2.302 Hg-N1 2.576 Cd-N1 2.415 
Hg-N2 2.537 Cd-N2 2.399 Hg-O1 2.656 Cd-O1 2.423 
C=O 1.236 C=O 1.236 C=O 1.232 C=O 1.228 
C-O 1.386 C-O 1.386 C-O 1.402 C-O 1.412 
 
Table 5.30 Torsion angles (°) derived computationlly for [LM(SeCN)2] structures  
Hg(SeCN)2 + His Cd(SeCN)2 + His Hg(SeCN)2 + Gly Cd(SeCN)2 + Gly 
Se1-C-N4 178.79 Se1-C-N4 178.45 Se1-C-N3 178.03 Se1-C-N2 178.2 
Se2-C-N5 176.36 Se2-C-N5 175.84 Se2-C-N2 177.04 Se2-C-N3 176.32 
N1-Hg-N2 83.87 N1-Cd-N2 87.79 N1-Hg-O1 64.67 N1-Cd-O1 96.81 
Se1-Hg-Se2 125.79 Se1-Cd-Se2 121.32 Se1-Hg-Se2 149.92 Se1-Cd-Se2 139.71 
Se1-Hg-N1 108.92 Se1-Cd-N1 111.15 Se1-Hg-N1 107.5 Se1-Cd-N1 112.35 
Se2-Hg-N2 99.18 Se2-Cd-N2 101.26 Se2-Hg-O1 111.58 Se2-Cd-O1 112.17 
Se1-Hg-N2 118.69 Se1-Cd-N2 116.85 Se1-Hg-O1 89.99 Se1-Cd-O1 96.81 
Se2-Hg-N1 112.6 Se2-Cd-N1 113.3 Se2-Hg-N1 100.81 Se2-Cd-N1 103.86 
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Figure 5.25 Compuationally optimized structures of [LM(SeCN)2] complexes 
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5.4.5 Antibacterial activity 
The in vitro anti-bacterial activity studies were performed with Cd(II) complexes against 
both gram positive as well as gram negative bacteria. Two complexes, (His)Cd(SeCN)2 
and (Gly)Cd(SeCN)2 exhibited antibacterial activity compared to the Cd(SeCN)2 except 
for K. pneumoniae, which showed resistance to all the tested compounds. The inhibition 
of Hg(SeCN)2was reported previously [160], while mercury complexes with glycine and  
histidine did not show significant antibacterial activity. The activities of the complexes 
are summarized in Table 5.31. 
Table 5.31 Antibacterial activities of [LM(SeCN)2] complexes  
Microorganisms  
Zone of Inhibition (mm) 
Hg(SeCN)2
*
 Cd(SeCN)2 [(His)Cd(SeCN)2] [(Gly)Cd(SeCN)2] 
E. coli - 25 35 22 
P. aeruginosa 10 20 18 32 
S. typhi 10 28 32 29 
S. aureus 22 20 22 20 
K. pneumonia 22 -- -- -- 
*Published work [160] 
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5.5 Interaction studies of Gold(III) complex using NMR spectroscopy 
This work reports the interaction of [Au(pn)]
3+ 
with some biologically important ligands 
such as Imt, Gly, Met, Im and His as shown in Figure 5.26 using 
1
H and 
13
C NMR 
measurements.  
 
 
Figure 5.26 Structures of ligands with carbon numbering for NMR studies 
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5.5.1 Interaction of [Au(pn)2]Cl3 with Thiourea and Imidazolidine-2-thione 
The interaction of Thiourea (Tu) and Imidazolidine-2-thione (Imt) was studied by 
1
H 
NMR. The 
1
H chemical shifts of free pn, [Au(pn)2]
3+ 
and interacted ligands such as Tu 
and Imt are shown in the Table 5.32. 
The proton spectrum of free thiourea (Tu) in D2O at 298 K shows a signal at 7.05 ppm 
corresponds to N-H protons. The study of interaction of [Au(pn)2]
3+ 
and Tu shows a 
change in chemical shifts of N-H protons correspond to coordinated pn in gold complex. 
The interaction of Imidazolidine-2-thione (Imt) with [Au(pn)2]
3+ 
 at 298 K in D2O was 
followed by 
1
H NMR. The proton spectrum of free Imidazolidine-2-thione in D2O shows 
signals at 3.50 and 7.94 ppm corresponding to C-H and N-H protons respectively. The 
study of interaction of [Au(pn)2]
3+ 
and Imt shows a change in chemical shifts of C-H and 
N-H protons of pn in the gold complex.  
The interaction of Tu and Imt was also studied by 
13
C NMR. The 
13
C chemical shifts of 
free pn, [Au(pn)2]
3+ 
 and interacted [Au(pn)2]
3+ 
 with Tu and Imt are given in the Table 
5.33. 
The carbon spectrum of free thiourea (Tu) in D2O is taken at 298 K. Signal at 182.72 
ppm corresponds to carbon (C=S) of Tu. An upfield chemical shift from 182.72 ppm to 
157.73 ppm of C=S carbon of the interacted Tu accounts for complexation with Au(III) 
centre. As a result, such complexation leads to one of the bound pn as mono-dentate 
ligand in the complex. The interaction of [Au(pn)2]
3+ 
 complex with Tu also leads to an 
into upfield chemical shift of carbons of the coordinated pn. 
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The carbon spectrum of free Imidazolidine-2-thione (Imt) in D2O is taken at 298 K. 
Signals at 44.07 and 183.07 ppm correspond to C-1 (CH2) and C-2 (C=S) carbons 
respectively. The larger change in chemical shift for C=S carbon of Imt is observed 
which could be attributed to ligation of C=S sulfur of Imt to Au(III). The evidence of S 
binding of Imt is also corroborated by the downfield shift of CH2 carbon of Imt. The 
smaller upfield chemical shift of CH2 carbon and the larger downfield chemical shift of 
C=S carbon indicate the binding of C=S sulphur of Imt towords Au(III) as a metal center. 
As a result, one of NH2 nitrogen bound pn may be replaced by C=S sulphur of Imt in 
[Au(pn)2]
3+ 
 complex. Therefore, one of coordinated bi-dentate pn may become mono-
dentate ligand in the gold(III) complex.  
From this study, it appeared that the binding of thione like Imidazolidine-2-thione (Imt) 
and thiourea (Tu) is probably occurring through S atom of Tu and Imt towards Au(III) 
centre in the complex at 298 K in D2O. The 
13
C NMR spectra of the interacted Au(III) 
complex show the deshielding of carbons of the bound pn as result of interaction with Tu 
and Imt. 
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Table 5.32 1H NMR data of [Au(pn)2]
3+ and interacted [Au(pn)2] 
3+ with Imt and Tu 
Compound H1-pn H2-pn       
Free pn 2.76 1.59     
 
[Au(pn)2]
3+
 2.96 1.93       
      C-H Imt N-H Imt 
 
Free Imt     3.5 7.94 
 
Imt + [Au(pn)2]
3+
 3.17 1.81 3.6 7.98   
          N-H Tu 
Free Tu         7.05 
Tu + [Au(pn)2]
3+
 2.94 1.9     7.08 
 
 
Table 5.33 13C NMR data of [Au(pn)2]
3+ and interacted [Au(pn)2]
3+  with Imt and Tu 
Compound C2-pn C1-pn       
Free pn 37.51 39.97     
 
[Au(pn)2]
3+
 37.27 41.41       
      C2-Imt C1-Imt   
Free Imt     44.07 183.35 
 
Imt + [Au(pn)2]
3+
 37.74 43.42 45.28 192.39   
          C=S(Tu) 
Free Tu         182.72 
Tu + [Au(pn)2]
3+
 37.6 41.93     157.73 
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5.5.2 Interaction of [Au(pn)2]Cl3 with Glycine and Methionine 
The interaction of Glycine (Gly) and Histidine (His) was also studied by 
1
H NMR. The 
1
H chemical shifts of free pn, [Au(pn)2]
3+ 
 and interacted ligands such as His and Gly are 
shown in the Table 5.34. 
The interaction of Glycine (Gly) with [Au(pn)2]
3+ 
at 298 K in D2O was followed by 
1
H 
NMR. The proton spectrum of free Glycine in D2O shows signals at 3.40 ppm 
corresponding to C-H proton. The study of interaction of [Au(pn)2]
+3  
and Gly shows no 
appreciable change in chemical shifts of C-H protons corresponding to the bound pn in 
the gold complex. 
The proton spectrum of free L-methionine (Met) in D2O at 298 K shows signals at 2.06, 
2.53, 2.00 and 3.73 ppm that correspond to protons numbered 5, 4, 3 and 2 respectively  
There is a slight change in chemical shifts of protons associated with bound pn in the 
gold complex as a result of interaction with Met. 
The interaction of Gly and Met was also studied by 
13
C NMR. The 
13
C chemical shifts of 
free pn, [Au(pn)2]
3+
 and interacted [Au(pn)2]
3+
 with Gly and Met are given in the Table 
5.35. 
The carbon spectrum of free Glycine (Gly) in D2O was taken at 298 K. Signals at 44.26 
and 173.26 ppm correspond to C-1 (CH2) and C-2 (C=O) carbons respectively. The 
change in chemical shift for C=O carbon of Gly could be attributed to ligation of C=O 
oxygen of Gly to Au(III). This is also corroborated by the smaller downfield shift of CH2 
carbon of Gly. As a result, one of NH2 nitrogen in bound pn may be replaced by C=O 
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oxygen of Gly in [Au(pn)2]
3+
 complex. Therefore, one of coordinated bi-dentate pn 
would become mono-dentate ligand in the gold(III) complex. 
The interaction of Methionine with [Au(pn)2]
3+ 
complex was also studied by 
13
C NMR 
spectroscopy. 
13
C NMR spectra of free and interacted Met with [Au(pn)2]
3+ 
 in D2O 
solvent are measured at 298 K. Chemical shifts at 14.76, 29.65, 30.47, 54.71 and 174. 98 
ppm corresponds to carbons numbered 5, 4, 3, 2 and 1 of free L-Methionine. The 
interaction of L-Methionine (Met) with gold(III) complex results in the change of 
chemical shifts of C-1 and C-2 of coordinated pn. The downfield chemical shifts of the 
pn carbons of the complex support the hypothesis of interaction of Met with gold(III) 
complex as given in Table 5.8. Apart from such changes, there is also a downfield 
chemical shift of the carbon directly bonded to S of Met. Such changes chemical shifts 
may be a sign of the interaction of Met through S towards Au(III) centre. 
From this study, it appeared that the binding of thioether like L-Methionine (Met) is 
probably occurring through S atom of Met towards Au(III) centre in the complex at 298 
K in D2O. The 
13
C NMR spectra of the interacted Au(III) complex show the deshielding 
of carbons of the bound pn as result of interaction with Met. 
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Table 5.34 1H NMR data of [Au(pn)2]
3+ and interacted [Au(pn)2]
3+ with Gly and Met 
Compound H1-pn H2-pn     
Free pn 2.76 1.59   
 
[Au(pn)2]
3+
 2.96 1.93     
      C-H Gly   
Free Gly  - -  3.4 
 
Gly + [Au(pn)2]
3+
 2.96 1.92 3.41   
        H2 Met 
Free Met  -  -   3.73 
Met + [Au(pn)2]
3+
 3.05 1.94   4.09 
 
Table 5.35 13C NMR data of [Au(pn)2]
3+ and interacted [Au(pn)2]
3+ with Gly and Met 
Compound C2-pn C1-pn         
Free pn 37.51 39.97 
 
    
 
Au(pn)2]
3+
   37.27 41.41         
      C-2 Gly C-1 Gly     
Free Gly     42.26 173.26     
Gly + [Au(pn)2]
3+
   37.57 41.76 42.34 173.44     
          C4-Met C1-Met 
Free Met     
 
  29.65 174.98 
Met + [Au(pn)2]
3+
   37.41 41.7     25.87 176.05 
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5.5.3 Interaction of [Au(pn)2]Cl3 with Imidazole and Histidine 
The interaction of Imidazole (Im) with [Au(pn)2]
3+
 complex was also studied by 
1
H NMR 
spectroscopy. The 
1
H chemical shifts of free pn, [Au(pn)2]
3+
, interacted Imidazole (Im) 
and Histidine (His) ligands are given in the Table 5.36 and Table 5.37 respectively. 
The interaction of Imidazole (Im) with [Au(pn)2]
3+ 
at 298 K in D2O was followed by 
 
proton NMR. The proton spectrum of free Imidazole (Im) in D2O shows signals at 6.97 
and  7.61 ppm related to HC=CH (free Im) and  N-CH=N (free Im) protons respectively. 
The interaction of [Au(pn)2]
3+ 
with Im causes downfield chemical shifts of HC=CH 
(bound Im) and  N-CH=N (bound Im) protons in gold(III) complex. There is a slight 
upfield chemical shift of protons associated with the bound pn in the gold complex as a 
result of interaction with Im. 
The 
1
H spectrum of free Histidine (His) in D2O at 298 K shows signals at 2.95, 3.06, 
3.82, 6.89 and 7.58 ppm that correspond to protons numbered 3(a), 3(b), 2, 5 and 6 
respectively. There is a slight upfield chemical shift of protons associated with the bound 
pn in the gold complex as a result of interaction with His. 
The interaction of Im and His with gold(III) complex was also studied by 
13
C NMR 
spectroscopy at 298 K in D2O. The 
13
C chemical shifts of free pn, [Au(pn)2]
3+
, interacted 
[Au(pn)2]
3+
 with Im and His are given in the Table 5.38 and Table 5.39 respectively.  
Signals at 122.55 ppm and 136.83 ppm corresponds to HC=CH and N-CH=N carbons of 
free Imidazole. The interaction of Imidazole with [Au(pn)2]
3+
 results in the downfield 
chemical shifts of C-1 and C-2 of coordinated pn as given in the Table 5.38. The slight 
upfield chemical shift of HC=CH and N-CH=N carbons of Imidazole may also be a sign 
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of the interaction of Imidazole through nitrogen donor atom (HC=N-CH) towards Au(III) 
center.  
The interaction of Histidine (His) with [Au(pn)2]
3+
 complex is also studied by 
13
C NMR 
spectroscopy. 
13
C NMR spectra of free and interacted His with [Au(pn)2]
3+
 in D2O 
solvent are measured at 25˚C. Signals at 29.00, 55.66, 117.63, 133.18, 137.18 and 174.72 
ppm corresponds to carbons numbered 3, 2, 5, 4, 6 and 1 of free Histidine. The 
interaction of Histidine with the gold(III) complex results in the change in chemical shifts 
of C-1 and C-2 of coordinated pn. The downfield chemical shifts of the pn of complex 
complex support the hypothesis of interaction of His with gold(III) complex as given in 
the Table 5.39. Apart from such changes, there are also downfield chemical shifts of 
Histidine carbons 2, 5 and 4; slightly upfield chemical shifts of carbon numbered 1 and 3 
i.e  176.35 ppm and 28.64 ppm respectively; and unchanged chemical shift of carbon 
numbered 6. Such significant changes in chemical shifts may reveal the interaction of 
Hist with Au(III) center.  
These experiments indicate that the binding of thione like imidazolidine-2-thione (Imt) 
and thioether (Tu); and thioether like Methionine (Met) through S towards Au(III) center. 
The 
13
C NMR spectra of the interacted Au(III) complex show the deshielding of carbons 
of bound pn as result of interaction with Imt, Tu and Met. 
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Table 5.36 1H NMR data of [Au(pn)2]
3+ and interacted [Au(pn)2]
3+ with Im 
Compound H1-pn H2-pn     
Free pn 2.76 1.59   
 
[Au(pn)2]
3+
 2.96 1.93     
      HC=CH Im N-CH=N Im 
Free Im     6.97 7.61 
Im + [Au(pn)2]
3+
 2.94 1.9 7.01 7.74 
 
Table 5.37 1H NMR data of [Au(pn)2]
3+ and interacted [Au(pn)2]
3+  with His 
Compound H1-pn H2-pn           
Free pn 2.76 1.59         
 
[Au(pn)2]
3+
 2.96 1.93           
      H3  (a) His H3 (b) His H2 His H5 His H6 His 
Free His     2.95 3.06 3.82 6.89 7.58 
His + [Au(pn)2]
3+
 2.92 1.88 
2.70, 3.06(f), 3.76, 
6.89 
7.70(i)  
2.92 3.02(i) 3.63, 7.59(f) 
    3.53   
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Table 5.38 13C NMR data of [Au(pn)2]
3+ and interacted [Au(pn)2]
3+ with Im. 
Compound C2-pn C1-pn     
Free pn 37.51 39.97   
 
[Au(pn)2]
3+
   37.27 41.41     
      HC=CH Im N-CH=N Im 
Free Im     122.55 136.83 
Im + [Au(pn)2]
3+
   37.52 41.8 122.22 136.55 
 
 
Table 5.39 13C NMR data of [Au(pn)2]
3+ and interacted [Au(pn)2]
3+ with His 
Compound C2-pn C1-pn             
Free pn 37.51 39.97           
 
Au(pn)2]
3+
   37.27 41.41             
      C-3 His C-2 His C-5 His C-4 His C-6 His C-1 His 
Free His     29 55.66 117.63 133.02 137.18 174.72 
His + [Au(pn)2]
3+
   37.78 38.4 28.64 55.91 117.86 133.38 137.18 176.35 
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6 CHAPTER 6 
SUMMARYAND CONCLUSIONS 
A novel series of gold(III) diamine complexes (1-7) with general formula, 
[Au(diamine)2]Cl3 have successfully been synthesized and characterized by using various 
analytical and spectroscopic techniques. The NMR and elemental analysis results 
strongly support the formation of a 1:2 complex of the type [Au(diamine)2]
+ 
with 
chelating ethylenediamine, propylenediamine or akyl substituted ethylenediamine 
ligands. 
15
N NMR showed that the nitrogens of five-membered ring of 
monoethylenediamine complex (8) has higher electron donation to gold(III) than that of 
the bis-ethylenediamine complex. Computational study shows that this complex has a 
slightly distorted square planar geometry. According to our biological assays, complex 
(1) with ethylenediamine is a more promising candidate as an anticancer agent than 
complex (4). Therefore, [Au(en)2]Cl3 might be a prospective chemo-preventative and 
chemotherapeutic agent against human gastric carcinogenesis.   
According to IC50 data, complex (1) with ethylenediamine ligand is a more prospective 
anticancer agent against prostate cancer PC3 cells.  The dose dependent studies showed 
that complex (1) was found to execute a powerful and promising cytotoxic effect on PC3 
cells which is comparable to that of cisplatin. These data also indicate that gold(III) 
complexes with specific ligands incorporated into the structural design such as complexes 
(2-5) may have the potential to overcome mechanisms inducing resistance to cisplatin, 
particularly in the gastric cancer SGC7901 cells.  
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The MTT results showed the effect of complexes (8-10) on prostate PC3 cancer cells 
growth, where the first two complexes (8) and (9) demonstrated inhibition in cancer cells 
growth, while the last complex (10) did not show any significant changes in cancer cells 
growth. Thus, complexes (8) and (9) might prove to be reasonably good candidates as 
anticancer drugs for prostate cancer. The MTT results also showed the effect of 
complexes (8-10) on gastric SGC7901 cells growth, where the first complex (8) 
demonstrated inhibition in cancer cells growth, while the last  two complexes (9) and (10) 
did not show any major changes in cancer cells growth. Thus, complex (8) might prove to 
be practically good candidate as anticancer drug for gastric cancer. The IC50 data for 
cisplatin sensitive A2780 and cisplatin resistant A2780 cis ovarian cancer cell lines show 
that [Au(en)Cl2]Cl (8) is relatively better cytotoxic agent than [Au(en)2]Cl3 (1). 
It is also interesting to note that mono(alkyldiamine)gold(III) complexes, 
[Au(diamine)Cl2]
1+
 complexes (8) and (9) show relatively better anticancer agents in the 
gastric cancer SGC7901 cells while [Au(diamine)2]
3+
 complexes (1-5) display 
comparatively better anticancer activity against the prostate PC3 cells as well as cisplatin 
sensitive A2780 and cisplatin resistant A2780 cis ovarian cancer cell lines. Since 
complex [Au(en)2]Cl3 (1) emerged as the best anticancer agent in this study, it is 
presently subjected to evaluation of in vivo anticancer properties. 
A new series of gold(III) complexes of general formula [(thione)2Au(diamine)]Cl3 
complexes (11-18) are reported here.  The solid state IR as well as 
13
C and 
15
N NMR data 
indicate that Au(III) center is bonded via sulfur of thiocarbonyl S=C<   site of the thiones 
and also chelated by the diamines from the trans side of coordinated thiones. 
Spectroscopic data were evaluated by comparisons with calculated data from the built 
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and optimized structure by GAUSSIAN 09 at the RB3LYP level with LanL2DZ bases 
set. These new Au(III) complexes based on mixed thione and diamine ligands are almost 
similar with the square planar structure of tetra-coordinate [Au(en)2]Cl3 complex.  
Since [Au(en)2]Cl3 type complex are relatively more toxic towards some cancer cell 
lines,  the [(thione)2Au(diamine)]Cl3 complexes may be a better alternate for 
[Au(en)2]Cl3 type complex.  The in vitro cytotoxic study of thione Au(III) complexes 
against C6 glioma cell line also leads to the conclusion that the structural features e.g. 
ring size of  thione ligand (Imt and Diaz) as well as Au(III) chelate size  with diamine 
(en, pn and bn)  may affect  in vitro cytotoxicity of the complex.   
In addition to the synthesis of gold(III) complexes, a series of Hg(CN)2 complexes (19-
24) of the type [Hg(CN)2(L)] (L= en, pn, N-Me-en, N,N'-Me2-en, N,N'-Et2-en and N,N'- 
ipr2-en) was also synthesized and characterized. The analysis of the complexes showed 
only one equivalent of alkyl diamine ligand involved in coordination to form a mercury 
complex. Complexes (19 and 20) have shown a good antibacterial activity towards 
different microorganisms. 
Moreover, some Cd(II) and Hg(II) complexes (25-28) of the type, [(L)M(SeCN)2] (L= 
Histidine or Glycine and M
2+
 = Cd
2+
 or Hg
2+
), were also prepared  and characterized by 
EA, mid-IR solution and Solid state NMR. The results reveal that the metal complexes 
with Histidine are more strongly coordinated than that of the corresponding Glycine 
containing metal complexes. The Cd(II) complexes have shown good zone inhibition 
towards different microorganisms, while no significant antibacterial activity was 
observed for the mercury complexes. 
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6.1 Future Studies 
 In the same line of Au(III) diamine complexes, Au(III) bipyridine  and Au(III) 
phenanthroline complexes can also be synthesized and evaluated in vitro for  
potential anticancer activity. 
 As in vitro anticancer activity of [Au(en)2]Cl3 and its derivatives was significantly 
promising towards some cancer cell line, further in vivo anticancer evaluation 
would be worth-while.  
 With same frame of mind, N-alkyl substituted imidazolidine-2-thione (N-R-Imt) 
can also be used to synthesize a new series of complexes with general formula, 
[(N-R-Imt)2Au(diamine)]Cl3 and evaluated in-vitro for potential anticancer 
activity. 
 As [(Imt)2Au(pn)]Cl3 complex has emerged as an excellent in vitro cytotoxic 
agent against C6 glioma cancer cell line, further in vivo cytotoxic evaluation for 
such complex is needed.  
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[Au(en)2]Cl3 and [Au(N-propyl-en)2]Cl3 on human cancer cell lines, Spectrochim. 
Acta - Part A, 79, 1196-1201 (2011).  
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Appendix B - Conference Presentations 
1. Poster presentation entitled “New [Au(DACH)2]Cl3 complexes: Synthesis, 
characterization, in vitro cytotoxicity and influence of stereochemistry on 
anticancer activity”  accepted in the 247th ACS National Meeting 2014 (March 
16-20, 2014) in Dallas, United States of America. 
2. Oral presentation entitled “Synthesis, characterization of new gold(III)-
alkanediamines complexes and their anticancer activity against gastric, prostate 
and ovarian cancer cell lines” in the ChemIndix 2013 on 5th November, 2013 at 
Gulf Hotel, Kingdom of Bahrain. 
3. Poster presentation entitled “New [(thione)2Au(diamine)]Cl3 complexes: 
Synthesis, Spectroscopic characterization and in vitro Cytotoxicity” in the 4th 
Scientific Saudi Conference (SSC4) on 30th April, 2013 at Umm Al-Qura 
University, Makkah, Kingdom of Saudi Arabia. 
4. Poster presentation entitled “Anticancer activity of new gold(III) complexes of 
[Au(en)2]Cl3 and its derivatives against human prostate and gastric cancer cell 
lines” in the 3rd Scientific Saudi Conference (SSC3) on 1st May 2012 at Al-
Khobar, Kingdom of Saudi Arabia. 
5. Poster presentation entitled “Synthesis, characterization and antiproliferative 
effect of [Au(en)2]Cl3 and [Au(N-propyl-en)2]Cl3 on human cancer cell lines” in  
the 2nd Scientific Saudi Conference (SSC2) on 29th  March, 2011 at Jeddah, 
Kingdom of Saudi Arabia. 
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